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The chemokine CXCL16 is a new member in the C-X-C subfamily of 
chemokines and signals through its sole receptor, CXCR6. Studies have suggested 
that CXCL16 could influence tumourigenesis and metastasis though this has not been 
conclusively elucidated. Moreover CXCL16 is commonly found in either a trans-
membrane or a soluble form. Recent studies have suggested that these forms are 
linked to different signalling mechanisms. As such, observations from past studies are 
believed to be confounded by this supposed dual role of CXCL16. Thus further work 
was required to elucidate the roles CXCL16 play in the establishment of cancers and 
metastasis. 
To elucidate novel roles of CXCL16 in the context of breast cancer metastasis, 
we hypothesised that CXCL16 plays a role in influencing breast cancer cell migration 
and metastasis. We tested this hypothesis by first profiling the expression of CXCL16 
in breast cancer histological samples and cell-lines. Then, we analysed the expression 
profiles of our tumour samples with archived clinicopathological data to determine 
relevant associations between CXCL16 expression and metastasis-related parameters. 
We ascertained if soluble CXCL16 could alter (a) breast cancer cell proliferation and 
(b) cell migration in a scratch-wound healing assay. We then screened a real-time 
PCR array for potential genes linked to the observations noted in our wound healing 
assays. 
Our expression profile data suggest that trans-membrane CXCL16 is down-
regulated in breast tumours as compared to normal tissue. CXCL16 expression was 
observed in both tumour tissue and tumour infiltrating lymphocytes, which seemed to 
interact with the tumour mass. A trend was observed between lymph node metastasis 
and trans-membrane CXCL16 expression whereby the down-regulation of CXCL16 
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was associated with an increase in lymph node metastasis, though this was 
statistically insignificant in our sample size. Down-regulation of tumour CXCL16 was 
also associated with the ER-/PR-/HER2+ expression pattern, which is a trademark of 
highly metastatic breast cancer cells. In-vitro experiments revealed that soluble 
CXCL16 increased both MDA-MB-231 and MCF-7 cell migration in scratch-wound 
healing assays while it did not alter cell proliferation. The conditioned media 
collected from these experiments were able to produce the same observations when 
transferred to new wound healing assays. The increased cell migration potential 
conferred by soluble CXCL16 was reversed by an inhibition of the ERK signalling 
pathway. Several ERK-related genes could possibly mitigate CXCL16-induced cell 
migration increase though these genes may not be directly linked to the CXCL16 
signalling cascade. One gene that appeared to be linked to the CXCL16 and ERK 
pathways, somatostatin receptor 2 (SSTR2), was the most eligible candidate from our 
screening experiments that seemed to account for the observations seen in the wound 
healing assays. Inhibition of SSTR2 per se increased cell migration but this was not 
witnessed when SSTR2 was inhibited in experiments containing soluble CXCL16. 
Our results thus show that soluble CXCL16 increases breast cancer cell 
migration and likelihood of metastasis while trans-membrane CXCL16 could delay 
the onset of metastasis. Further experiments are required to determine the molecular 
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1.1 BRIEF INTRODUCTION OF CHEMOKINES AND THEIR RECEPTORS 
 Chemokines are a class of cytokines that have been widely regarded for their 
role in mediating chemotaxis (i.e. chemotactic cytokines) and immunological 
responses (1-3). They generally function as chemo-attractants that guide migrating 
cells to their destination and as inflammatory response mediators that promote 
immune responses. Chemokines typically induce signalling mechanisms in cells by 
binding to their respective chemokine receptors that are coupled to G-Proteins (1, 3).  
Chemokines are typically classified according to their structural conformity 
(2-3). This is generally dependent on the conserved patterns and sequences of amino 
acids resident within these chemokines, such as the 4 cysteine residues (in most 
chemokines) that interact with each other to provide these chemokines with their 
respective 3-D structures. Chemokines can be divided into 4 sub-categories according 
to their structural conformities, namely the CC ligand chemokines (CCL), the CXC 
ligand chemokines (CXCL), the C ligand chemokines (XCL) and the CX3C ligand 
chemokine (CX3CL) (2-3).  
CCL chemokines generally contain 4 cysteine residues, 2 of which are 
adjacent to each other at the N-terminus, while a small number have been shown to 
contain 6 cysteine residues (e.g. C6-CC chemokines such as CCL1 and CCL15) (2). 
In CXCL chemokines, the 2 N-terminal cysteine residues are separated by one amino 
acid (referred to as ‘X’). This group can be further subdivided into 2 groups, namely 
chemokines containing the glutamic acid-leucine-arginine conserved motif (i.e. ELR 
for short) and those without the ELR motif (2). The ELR motif confers chemokines 
such as CXCL1 and CXCL2 with the ability to up-regulate inflammatory responses 
by attracting neutrophils with CXCR1 and CXCR2 receptors (2, 4).  XCL chemokines 
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differ from the other chemokines in that they contain only 1 cysteine residue at their 
N-terminal. Two chemokines, XCL1 and XCL2, have been previously described in 
this category (2, 5). The final category, CX3CL chemokine is made up of a single 
member, the chemokine CX3CL1 (also known as fractalkine) where 3 amino acids 
separate the 2 N-terminal cysteine residues in this chemokine (2, 6). 
There are about 18 chemokine receptors mediating the response of 
approximately 47 chemokines, (2, 7) and all the receptors are believed to be G-Protein 
Coupled Receptors (GPCRs) (1, 8-9). The receptors are classified according to their 
corresponding chemokine subcategories, namely, CCL chemokines bind to CCR 
receptors, CXCL chemokines bind to CXCR receptors, XCL chemokines bind to 
XCR1 and CX3CL1 binds CX3CR1. Some individual chemokines also have affinity 
for several receptors and vice versa. For example, CCL5 has been shown to bind with 
CCR1, CCR3 and CCR5 (10) while both known C chemokines bind to XCR1 (2, 5). 
Studies have thus shown that such cross-affinities between chemokines and 
chemokine receptors play a part in regulating the responses brought about by 
chemokines in several physiological responses such as inflammation (7, 10).  
 
1.2 CHEMOKINE CXCL16 AND ITS RECEPTOR CXCR6 
The chemokine CXC Ligand 16 (CXCL16) is a new member in the CXC 
subfamily of chemokines (11). This special chemokine is one of only two chemokines 
found to be present in both trans-membrane and soluble forms. The other known 
chemokine with similar properties is CX3CL1 (6). The soluble form of CXCL16 is 
secreted only when trans-membrane CXCL16 is cleaved by metalloproteases such as 
the ADAM10 (A Disintegrin And Metalloprotease like domain 10) and ADAM17 
metalloproteases (12-16).  To this effect, the exact ectodomain cleavage sites at which 
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ADAM10 and ADAM17 act upon are still being determined. In addition, Ludwig et al 
(2005) have shown that while CXCL16 is cleaved by ADAM10 through constitutive 
cleavage mechanisms, ADAM17 works through inducible cleavage mechanisms (15).   
Structurally, CXCL16 (Fig 1) is made up of a CXC chemokine domain that 
mediates its biological activity, a glycosylated mucin-like stalk where ectodomain 
cleavage occurs, a transmembrane domain and a cytoplasmic tail which could 
possibly contain SH2 binding domains (6, 11, 17).    
The chemokine receptor CXCR6 is a G-protein coupled receptor and is the 
only known chemokine receptor that CXCL16 binds to (11, 17). The downstream 
signalling pathways upon receptor activation are still being established, with some 
studies implicating the Gi signalling pathway as the main circuit through which 
CXCL16 exerts its biological functions. For example, Chandrasekar et al (2004) (18) 
have established in aortic smooth muscle cells that CXCL16 signals through Gi 
proteins and the Akt pathway. Meijer et al (2008) (19) have also noted the activation 
of Gi proteins in breast carcinoma cells upon trans-membrane CXCL16 activation of 
CXCR6. Interestingly, soluble CXCL16 did not activate Gi proteins upon binding to 
CXCR6 and the biological observations noted (discussed in the following section) 
differed from that of trans-membrane CXCL16, thus indicating that CXCL16 signal 
















Figure 1: Structure of chemokine CXCL16 
There are two forms of CXCL16, the trans-membrane (left) and the soluble (right) 
form. Trans-membrane CXCL16 is structurally made up of three domains: the 
chemokine domain which binds its receptor CXCR6, the glycosylated mucin-like 
stalk and the cytoplasmic domain that contains a potential SH2 binding site (labelled 
YXPV). Soluble CXCL16 is derived from the cleavage of trans-membrane CXCL16 









1.3 ROLE OF CXCL16-CXCR6 PATHWAY IN INFLAMMATORY 
RESPONSES 
Various studies have shown that CXCL16 and CXCR6 are expressed in a 
variety of cell-types. In the early years following the discovery of CXCL16, many 
groups focused on analysing the roles CXCL16 and CXCR6 play in leukocyte 
recruitment and vascular inflammation. This was probably due to the fact that 
CXCL16 was first shown to be expressed in dendritic cells and sinus-associated cells 
of the splenic red pulp, in a mouse model (11). Wilbanks et al (2001) (17) later 





 monocytes derived from peripheral leukocytes and in tonsil-derived 
CD19
+
 B cells.  
In the context of inflammatory responses, the expression of CXCR6 has also 
been characterised predominantly in T cells (11, 17, 20-24). CXCR6 expression has 
been widely observed in CD4+ (both Th1 and Th2 cells), CD8+ T cells and Natural 
Killer T (NKT) cells. When there is co-presence of DC cells expressing CXCL16 and 





interactions via the CXCL16/CXCR6 pathway could further enhance the activation of 
T-cells and the eventual inflammatory responses (11, 25). This interaction gives 
CXCL16 and CXCR6 important relevance in T-cell implicated diseases such as 
rheumatoid arthritis. 
The two forms of CXCL16 have been shown to play different roles in several 
circumstances. In general, trans-membrane CXCL16 behaves like an adhesion 
molecule (26) towards cells expressing CXCR6 while soluble CXCL16 is believed to 
be a strong chemo-attractant (11, 17, 26-27) for CXCR6-expressing cells. While it is 
generally regarded that chemotaxis is mediated by the Gi signalling pathway, 
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Shimaoka et al (2004) (26) demonstrated that the adhesion of CXCR6-expressing 
cells to trans-membrane CXCL16 does not require a functional Gi pathway. This 
brings to light once again that the downstream signalling processes with regards to 
CXCL16 and CXCR6 are not straightforward.   
The aforementioned studies have thus elucidated that the CXCL16/CXCR6 
interaction functions largely to allow the retention of CXCL16/CXCR6-expressing 
inflammatory cells at sites of inflammation upon site-specific chemo-attraction. 
Indeed, CXCL16 expression can be up-regulated by pro-inflammatory cytokines 
interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) (12, 28). This 
essentially enables the opportunity for localised attraction of inflammatory cells that 
express CXCR6 to sites mounting an immune response through up-regulation of 
trans-membrane CXCL16. Of note, van der Voort et al (2005) (29) highlighted the 
presence of these sequential processes in rheumatoid arthritis patients. 
While the studies above have analysed the role of the CXCL16/CXCR6 
signalling pathway in inflammatory responses, little is known about the role of the 
pathway in normal epithelial cell growth and differentiation, primarily because the 
focus so far has been on the role of CXCL16 in mediating inflammatory responses. 
Notably, the expression and signalling of CXCL16/CXCR6 may also be tissue-type 
specific in normal cells. For example, the expression of CXCL16 was previously 
found to be absent in normal colon cells (30) and prostate cells (31) but constitutively 
present in normal skin tissue (32). Also, in the normal human keratinocyte cell line 
HaCaT, the expression of CXCL16 was not modulated by pro-inflammatory 
cytokines interleukin-4 (IL-4), TNF-α and IFN-gamma (32). This differs from some 
of the cases described above (12, 28) where IFN-γ and TNF-α up-regulated CXCL16 
expression in normal vascular smooth muscle cells. Thus it is possible that CXCL16 
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could be functioning in other roles, other than in its conventional role of up-regulating 
inflammatory responses, in these skin cells and other normal cell-types.     
 
1.4 ROLE OF CHEMOKINES IN CANCERS 
The role of several chemokines and their receptors in promoting 
tumourigenesis and metastasis is of immense interest since several groups have 
reported supporting evidences to show that chemokine signalling plays an integral 
part in the development and aggressiveness of tumours. A large amount of work has 
been done in this area and these evidences have been reviewed in detail by O’Hayre et 
al (33) and Vandercappellen et al (34). It is thus known and widely accepted that 
several intrinsic signalling pathways are activated by these chemokines and their 
receptors (e.g. chemokines CXCL12, CCL19, etc) and such networks contribute to the 
development of tumour masses at both primary and secondary sites. However, these 
studies have also revealed that several chemokines, such as CCL2 and CCL3, also 
exhibit both pro and anti-tumourigenic effects in different tumours and contexts (33). 
As such, more work is still required to determine the precise effects each chemokine 
produce on the respective tumours and the signalling mechanisms that elucidate these 
effects before definite therapies are formulated to target complex signalling pathways 
regulated by chemokines. 
 
1.5 INVOLVEMENT OF CXCL12/CXCR4 IN TUMOUR PROLIFERATION 
AND METASTASIS     
Of noteworthy mention where chemokines are concerned, the chemokine 
CXCL12 and its receptor CXCR4 have arguably presented the most compelling 
evidences to show that chemokines play significant roles in tumour cell proliferation 
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and metastasis (33-36). Much work has been done on this signalling pathway, with 
several studies particularly implicating CXCR4 in cancer cell migration to secondary 
sites.  Moreover CXCR4 has been shown to be expressed in 23 different types of 
cancer, thereby raising the belief that it plays a universal role across all tumour types 
in promoting tumourigenesis and particularly metastasis (36). As such, it is probable 
that several other chemokine signalling pathways could also play a potent and 
universal role in promoting metastasis by directly stimulating the tumour 
microenvironment (and increasing the migratory potential of cells) and priming 
potential secondary sites by ‘promoting’ specific niche sites for the establishment of 
metastases. Work on the latter will perhaps be an important area for analysis in the 
coming years since recent studies have shown that several chemo-attractants such as 
the pro-inflammatory mediators S100A8 and S100A9 may be crucial for the 
establishment of secondary metastases since they are able to ‘earmark’ potential 
metastatic sites for tumour cells and other pre-cursor mediator cells, such as Vascular 
Endothelial Growth Factor Receptor 1 (VEGFR1)-positive haematopoietic bone 
marrow cells, to dock into for metastases establishment (37-40). As such, this 
speculation is of importance and thus warrants further analysis.      
While chemokines such as CCL2, CXCL8 and CXCL14 have been shown to 
exhibit similar effects on tumours as does CXCL12 (41-42), more evidences are still 
required to determine if these and other chemokines play a role similar to that of 
CXCL12 and if these chemokines are important for the establishment of metastases. 
One such chemokine signalling pathway, the novel CXCL16/CXCR6 pathway, is the 




1.6 ROLE OF CXCL16-CXCR6 SIGNALLING PATHWAY IN CANCERS 
Recently, many groups have devoted interest towards elucidating the role of 
CXCL16 and its receptor CXCR6 in promoting tumourigenesis and metastasis. There 
are 2 reasons for this interest: first, as described above, CXCL16 and CXCR6 play an 
important role in the induction of T-cell mediated inflammatory responses and these 
responses have also been widely witnessed in several tumours. Indeed, CXCL16 is a 
potent chemo-attractant and could thus also serve to mediate the establishment of 
secondary metastatic sites. Second, CXCL16-CXCR6 signalling pathways, being 
novel, have not been conclusively studied in the context of chemokine-mediated 
tumourigenesis and metastasis but preliminary studies in this area have already 
provided some interesting findings and will be discussed here.     
It is not until a couple of years ago that several groups witnessed the 
expression of CXCL16 and CXCR6 in several tumour types. Seidl et al (2007) (43) 
noted the expression of CXCR6 in primary and metastasised melanoma patient 
samples but not in melanoma cell lines. Lu et al (2007) (44) noted high levels of 
soluble CXCL16 in the conditioned media of the highly metastatic prostate cancer cell 
line PC3 as compared to the less aggressive LNCaP prostate cell line from which the 
PC3 cells were derived from. The group went to speculate that CXCL16 could thus 
play a contributory role in prostate cancer progression. They followed up with 
evidence to show that soluble CXCL16 was expressed in several cancer cell-lines 
(prostate, breast and lung) and CXCR6 was expressed in prostate cancer patient 
samples at the protein level. Both CXCL16 and CXCR6 were also elevated in 
metastatic prostate cancer tissues at the mRNA level (45). They also demonstrated 
that CXCL16 and CXCR6 were induced further in prostate epithelial cells by pro-
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inflammatory cytokines TNF- α and IL-1β, similar to that noted earlier in vascular 
cells (12). 
Perhaps Lu et al’s (2008) (45) most striking observation was that soluble 
CXCL16 induced prostate cancer cell migration and invasion in vitro, thus providing 
evidence to support the speculation that CXCL16 participates in metastasis. In fact, 
another study undertaken by Hu et al (2008) (46) has substantiated Lu and colleagues’ 
findings and have also elucidated that soluble CXCL16 could stimulate Matrix 
Metalloproteinases (MMP) 2 and 9 activity in LNCaP cells and thus play a probable 
role in prostate tumour metastasis to bone. Moreover, the group also noted the 
expression of trans-membrane CXCL16 in human osteocytes in vivo and went on to 
speculate that the bone could thus be a natural niche for metastasising prostate cancer 
cells that express CXCR6. 
Wagsater et al (2004)’s (47) initial work on rectal cancer determined that 
CXCL16 protein expression was down-regulated in cancer tissues as compared to 
normal tissues. Moreover, CXCL16 protein expression in tumour-associated 
macrophages (TAM) was much less than expression levels witnessed in macrophages 
found in normal tissues. However, the team also determined that genetic expression of 
CXCL16 was not down-regulated in tumour tissues and the decrease in the protein 
levels in tumour tissues was likely due to translational mechanisms that control the 
expression of CXCL16 in tumour tissues. The group also determined in a separate 
study that CXCR6 was expressed in normal epithelial cells while it was either down-
regulated or not expressed in cancer tissue from patient surgical samples (48). 
Moreover, it was also observed in a western blot analysis of tumour samples that 
almost half the number of samples analysed had a down-regulation of CXCR6 as 
compared to their adjacent normal tissue. Based on these early works, the down-
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regulation of both CXCL16 and CXCR6 thus seemed concomitant and may have a 
larger impact on immunological responses that could affect colorectal tumourigenesis 
and metastasis. In fact, Hojo et al’s (2007) (30) report highlighted a correlation 
between trans-membrane CXCL16 expression by colon cancer cells and tumour 
infiltrating lymphocytes (TILs) at tumour sites. However, in significant contrast to 
Wagsater et al’s study (47), the group witnessed an up-regulation of trans-membrane 
CXCL16 in patient tumour tissues as compared to the adjacent normal mucosa. This 
up-regulation was not only correlated to the presence of a large amount of TILs at the 
tumour sites, but was also associated with the good prognosis of these patients having 
tumours with high CXCL16 expression. Hojo and colleagues’ work was thus the first 
comprehensive analysis that suggested that CXCL16 had a wider impact on colorectal 
cancer prognosis and its expression was a good prognosis marker. 
Similar to the case of colorectal cancer, Wente et al (2008) (49) also proposed 
the use of CXCL16 as a potential diagnostic marker for pancreatic ductal 
adenocarcinoma (PDAC). They noted higher amounts of both trans-membrane and 
soluble CXCL16 in pancreatic cancer patient tissues and sera, with notable amount of 
CXCL16 expression at the invasive front of the tumour. The expression of CXCR6 in 
tumour tissues was also higher in these patients. Interestingly, the group determined a 
functional aspect of CXCL16 whereby CXCL16 significantly increased the invasive 
capability of PDAC cells in vitro while not affecting cell growth and viability. This 
supports a possible mediatory role of CXCL16 in cancer metastasis. Another related 
study by members from the same group noted the expression of CXCR6 in activated 
polymorphonuclear neutrophils (PMNs) found in the tumours of patient samples, 
while not detecting these PMNs in peripheral blood from these patients (50). The 
presence of activated CXCR6-positive PMNs at tumour sites is an interesting 
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observation, given that the presence of such PMNs at tumour sites has not been 
described previously.  Given that PMNs play an important part in mediating 
inflammatory responses, the role of these CXCR6-expressing PMNs in influencing 
tumourigenesis and metastasis would be an interesting focus for analysis.  
Airoldi et al (2008) (51) recently reported an interesting observation involving 
the metastasis of neuroblastoma (NB) cells to the bone marrow. While all metastatic 
NB cells expressed CXCR6, these cells were not chemotactically attracted to 
CXCL16 though. However, taking into account that all metastatic cells express 
CXCR6, the study has speculated the likelihood of these cells being retained in the 
bone marrow through their interaction with CXCL16-positive stromal cells in the 
bone marrow. It could be further speculated that specific niches expressing trans-
membrane CXCL16 could be prime areas for these cells to metastasise to. If proven, 
this would further implicate chemokines as chemical beacons for the demarcation of 
pre-metastatic niches and thereby add a further dimension to the interest in the pre-
metastatic niche story. 
In the context of breast cancer, Matsumara et al (2008) (23) demonstrated that 
ionising radiation therapy induced soluble CXCL16 secretion in breast tumour cells 
and this in turn primed the tumour environment to be more immunogenic. This 
enhanced the recruitment of anti-tumour T effector cells to tumour sites and increased 
anti-tumour immunological responses at these sites. In another interesting study, Ju et 
al (2007) (52) first noted the up-regulation of CXCL16 expression and secretion by 
the serine threonine kinase Akt-1 in mouse mammary epithelial tumour cells. They 
went on to propose through a proteomics analysis that Akt-1 could positively mitigate 
the migratory phenotype of mouse mammary tumour cells by soluble CXCL16-
mediated paracrine signalling. This interesting observation on cell migration certainly 
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requires further analysis, especially in the context of human mammary tumour cells 
and beyond the jurisdiction of Akt-1. 
Perhaps, the most striking study involving CXCL16 and CXCR6 in the 
context of human breast cancer was recently described by Meijer et al (2008) (19). In 
this study, the group demonstrated the dual roles of soluble and trans-membrane 
CXCL16 whereby trans-membrane CXCL16 inhibited cancer cell proliferation while 
soluble CXCL16 increased cell proliferation. The inhibitory action by trans-
membrane CXCL16 was mediated by CXCR6 and the Gi signalling pathway while 
the stimulatory role by the soluble form was not mediated by Gi but by an 
undetermined signalling pathway. This was indeed the first report that elucidated 
mechanistic and functional differences in CXCL16-CXCR6 signalling cascades, 
leading to the speculation of a new paradigm to the CXCL16-CXCR6 signalling story 
in the context of cancer biology. Taking this into account, the dual roles of CXCL16 
certainly confounds much that has been deciphered thus far about the role of CXCL16 
in tumourigenesis and metastasis and thus more studies are required even for the 
cancer types described above before definitive roles of CXCL16 can be firmly 
elucidated. Some differences noted when analysing CXCL16 and CXCR6 functions 
in different cancer types may have themselves resulted from simply observing the 
effects mediated by a single form of CXCL16 (either the trans-membrane or soluble 
form roles) while discounting the effects mediated by the other form. Because 
CXCL16 happens to be present in both forms in most instances, it is thus reasonable 
to suggest that there is a balance mediated by both CXCL16 mechanisms and a net 
threshold level could determine the eventual response.   
Apart from all the functional aspects of both CXCL16 forms described above, 
Morris et al (2008) (53) determined in a unique epigenetics study that CXCL16 
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behaved like a tumour suppressor gene in renal carcinoma cells. In this study, 
CXCL16 gene was found to be hypermethylated and thus its expression was 
suppressed. When CXCL16 was re-expressed in a renal tumour cell-line, the growth 
of cells was reduced. This study thus adds a further dimension to the roles of CXCL16 
in tumourigenesis and it remains to be established if CXCL16 is an epigenetically 
regulated tumour suppressor gene in other cancer types.  
 
1.7 HYPOTHESIS AND AIMS 
Hypothesis 
In this study we hypothesised that CXCL16 plays a role in mediating breast 
cancer metastasis and particularly breast cancer cell migration. The studies reviewed 
in the previous section have given rise to a new paradigm, where it is likely that both 
soluble and trans-membrane CXCL16 play different roles in tumourigenesis and 
metastasis. These roles thus require further analysis as current information is 
insufficient to clearly understand the effects CXCL16 bestow upon breast tumour 
cells and the changes these cells go through as a result of being exposed to CXCL16. 
Thus, we investigated the specific role of CXCL16 in influencing breast cancer 
progression in a pathoclinical context where we attempted to determine the effects of 
trans-membrane CXCL16 on breast cancer progression and metastasis. We also 
determined, through a set of in-vitro experiments, if excess soluble CXCL16 can 







We addressed the hypothesis with the following aims: 
1. Profiling CXCL16 and CXCR6 mRNA expression in breast cancer cell-lines by 
RT-PCR, to determine expression patterns in breast cancer cells with varying 
metastatic potential. 
2. Characterising trans-membrane CXCL16 expression via immunohistochemistry, in 
breast primary tumour and adjacent-to-tumour normal patient histological samples in 
a breast tissue microarray (TMA) to determine if patient tumour samples reveal trends 
of CXCL16 expression and if these trends have wider clinicopathological implications 
(i.e. if CXCL16 expression is associated with common breast cancer-linked 
clinicopathological parameters)  
3.  Determining if soluble CXCL16 treatment can accelerate cell proliferation of a 
poorly metastatic and highly metastatic breast cancer cell-line in vitro. 
4. Using a well-established model commonly utilised to study cell migration, the in 
vitro scratch wound healing model (54), to determine if soluble CXCL16 treatment 
can increase the rate at which inflicted wounds heal and if this is primarily due to an 
increase in cell migration into the wound area. 
5. Determining if a potent Extracellular signal-Regulated Kinase (12) (12) pathway 
inhibitor, U0126, can alter any observed effects of CXCL16 treatment in the wound 
healing model (The ERK pathway is believed to be the first signalling pathway 
activated in this model during the healing process (55). Increasing evidence has also 
implicated this pathway as an important mediator of metastasis (56)). 
6. Determining if conditioned media from CXCL16-treated wound healing setups can 
program cells in untreated, independent wound healing setups to adopt similar 
migratory characteristics as that seen in the former setups. 
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7. Determining changes in gene expressions as a result of CXCL16 and 
CXCL16/U0126 treatments and elucidating molecular players that participate in the 
effects mediated by CXCL16, using a SYBR Green Real-Time PCR metastasis-
related gene expression array. These changes in metastasis-related gene expressions 


























2. Methods and Materials 
 
2.1 CELL-LINES 
MCF10A, MDA-MB-231, MDA-MB-436, MCF-7 and HCC1937 cell lines 
were obtained from American Type Culture Collection, ATCC. MCF10AT1K is a 
Ras-oncogene transfected derivative of the MCF10A cell line. For this study, only 
total RNA from MCF10A, MCF10AT1K, MDA-MB-436 and HCC1937 cells were 
required for gene expression profile analysis and they were kindly provided by A/P 
Prakash Hande and Ms Anuradha Ponnepali of the Dept of Physiology, Yong Loo Lin 
School of Medicine, National University of Singapore. Details describing the 
characteristics of these cell-lines are found in the ATCC webpage 
(http://www.atcc.org/) and relevant details pertaining to this study are summarised in 
Table 1. 
MDA-MB-231 and MCF-7 cells were utilised for the majority of experiments 
carried out in this study and were cultured in high glucose DMEM culture media 
(Sigma Aldrich) supplemented with L-glutamine, 10% fetal bovine serum (Gibco, 
Invitrogen), 1% Penicillin Streptomycin (stock containing 10,000 units of penicillin 
(base) and 10,000 µg of streptomycin (base)/ml utilizing penicillin G (sodium salt) 
and streptomycin sulfate in 0.85% saline; Gibco, Invitrogen) and sodium bicarbonate 
(3.7g/L) (Sigma Aldrich). Cells were cultured in T75 culture flasks prior to 
experiments and all cell-culture experiments were maintained in an incubator set at 






Table 1: General characteristics of cell-lines utilised in this study 
Cell-line Disease Mets 
status 
Source 
MCF10A Non-malignant - Non-tumourigenic epithelial cells 
derived from cystic fibrosis 
patient 
MCF10AT1K Pre-malignant - T24 c-Ha-ras oncogene-
transfected MCF10A cells 
HCC1937 Primary ductal 
carcinoma 
- Patient with TMN stage IIA grade 
3 mammary tumour 
MCF-7 Adenocarcinoma Poorly 
metastatic 
Derived from patient metastatic 
site by pleural effusion  
MDA-MB-436 Adenocarcinoma Highly 
metastatic 
Derived from patient metastatic 
site by pleural effusion 
MDA-MB-231 Adenocarcinoma Highly 
metastatic 
Derived from patient metastatic 
site by pleural effusion 
 
2.2 RECOMBINANT PROTEINS AND INHIBITORS 
 Soluble recombinant human CXCL16 (herein referred to as soluble CXCL16) 
was purchased in lyophilized form from R&D Systems (catalogue number: 976-CX) 
and re-suspended in sterile PBS containing 0.1% bovine serum albumin (Sigma 
Aldrich) to a final stock solution concentration of 25µg/ml. Human CXCL16-specific 
goat anti-human polyclonal antibody was purchased in lyophilized form from R&D 
Systems (catalogue number: AF976) and re-suspended in sterile PBS to a final stock 
solution concentration of 100µg/ml. The ERK pathway-specific inhibitor U0126 was 
purchased from Biosource, Invitrogen (catalogue number: PHZ1283) and dissolved in 
Dimethyl Sulfoxide (DMSO) (Sigma Aldrich) to a final stock concentration of 10mM. 
Required dilutions of U0126 for cell culture were made by dissolving the required 
stock volumes in DMEM and filter sterilizing the final solution through a 0.2µm filter 
before use. The somatostatin receptor 2 (SSTR2) inhibitor CYANAMID 154806 
trifluoroacetate salt (CYN) was purchased from Sigma Aldrich (catalogue number: 
C2490) and dissolved in sterile distilled water to a final stock concentration of 2mM. 
All stock solutions were stored at -20°C.  
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2.3 RNA EXTRACTION AND REVERSE-TRANSCRIPTION 
Where gene expression patterns were analysed, cells were harvested from 
culture flasks or 6-well plates by trypsinisation and washed twice with sterile PBS. 
Total RNA from cells was extracted using an RNeasy Mini RNA extraction kit 
(Qiagen), according to the manufacturer’s instructions. Examination of 
quantity/quality of extracted total RNA was carried out on the Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific) by spectrophotometry and/or the 
Agilent 2100 Bioanalyser machine using an RNA 6000 LabChip kit (Agilent 
Technologies) according to the manufacturer’s instructions. All extracted total RNA 
samples were stored as small aliquots at -80°C. Aliquots were used only once after 
thawing. 
Reverse transcription (RT) of total RNA for first-strand cDNA synthesis was 
carried out with Superscript IIITM Reverse Transcriptase kit (Invitrogen). Each RT 
reaction mixture was mixed to a final concentration of 1µg total RNA in a 20µl 
reaction volume. First, to a nuclease-free microcentrifuge tube, 1µl of 50 µM 
oligo(50) (Sigma-Proligo), 1µl of 10mM dNTP Mix (Promega) and 1µg of total RNA 
was added and made up to a final volume of 13µl with sterile distilled water. The 
mixture was heated at 65°C for 5 minutes and quick-chilled on ice for at least 1 
minute. The contents of the tube were briefly centrifuged and 4µl of 5X First-Strand 
Buffer, 1µl of 0.1M DTT, 1µl of Superscript IIITM Reverse Transcriptase (200 
units/µl) (all contents provided with Superscript IIITM RT kit) and 1µl sterile distilled 
water were added to make a final reaction volume of 20µl. After mixing the contents 
with gentle pipetting, reverse transcription was commenced by incubating the reaction 
mixture at 50°C for 60 minutes. Thereafter the mixture was incubated at 70°C for 15 
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minutes to inactivate the reaction and synthesised cDNA samples were stored at -
20°C. 
 
2.4 POLYMERASE CHAIN REACTIONS 
Polymerase Chain Reaction (PCR) amplification reactions on the 
aforementioned cDNA samples were carried out to analyse expression profiles of 
genes stated in Table 2. Primer sequences for human CXCL16 and CXCR6 were 
obtained from a previous study published by Hojo et al (2007) (30) and shown to 
amplify the specific product of interest (product size indicated in Table 2). For 
analysing the housekeeping gene GAPDH, each 20µl PCR reaction mixture was made 
up of the following: 2µl GoTaq
®
Flexi 5X Green buffer (Promega), 0.5µl of 10mM 
dNTP Mix (Promega), 2µl of 25mM MgCl2 (Promega), 1µl each of gene-specific 
forward and reverse primers (10µM) (synthesised by Sigma-Proligo), 0.5µl of cDNA 
(corresponding to 25ng of total RNA), 0.2µl of GoTaq
®
Flexi DNA Polymerase(5 
units/µl) (Promega) and 12.8µl sterile distilled water. For the other genes of interest, 
the amount of cDNA in each reaction volume was increased to 2µl (corresponding to 
100ng of total RNA) while the amount of sterile distilled water was reduced to 11.3µl. 
All other component volumes were kept unchanged.  
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The PCR cycling parameters were configured in a thermocycler (Applied 
Biosystems) in the following manner: initial denaturation at 94°C for 30 seconds 
followed by denaturation at 30 seconds, annealing at 60°C for 60 seconds (for 
CXCL16 and CXCR6) and at 74°C for 30 seconds (for GAPDH), extension at 72°C 
for 90 seconds and 28 cycles (for CXCL16 and CXCR6) and 72°C for 60 seconds and 
25 cycles (for GAPDH) and a final elongation step at 72°C at 7 minutes. All reactions 
were stopped by cooling to 4°C at the end of the final step. 
At the end of PCR, 10µl of each PCR product was loaded into a 1.5% 
Ethidium Bromide-incorporated agarose gel and subjected to electrophoresis. Gene 
expression patterns were visualised by UV radiation thereafter. 
 
2.5.1 BREAST TUMOUR PATIENT HISTOLOGICAL SAMPLES AND 
TISSUE MICROARRAYS (TMA) 
Breast tissue microarrays (TMA) that were constructed and characterized 
previously by the Department of Pathology, National University of Singapore (NUS) 
were utilized to study CXCL16 protein expression patterns via 
immunohistochemistry, in normal and breast tumour tissues. Ninety-seven breast 
cancer patient samples and 97 normal breast tissue samples from the National 
University Hospital of Singapore were selected for the construction of the TMAs, as 
described previously (57). The patients’ age ranged from 29 to 86 years and the 
average age was 54 years. Of the 97 tumour patients, 44 had lymph node metastases 
and the status for 2 cases was unknown. Moreover, 8 patients had histologic grade 1 
tumours, 40 patients had grade 2 tumours, and 40 patients had grade 3 tumours while 
the grading for 9 cases were unknown. Other breast cancer-linked clinicopathological 
patient information, such as Estrogen Receptor (ER), Progestrone Receptor (PR), and 
HER2 protein expression profiles and patient survival data were obtained from 
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archives maintained at the Department of Pathology, NUS. Normal tissue sections in 
TMAs were harvested from the normal margins of excised tissues from patients 
suffering from breast cancer. The tumour TMA and normal TMA sample sections are 
thus patient-matched. 
In addition to the TMA, 5 full paraffin-embedded histological sections each of 
normal breast and breast tumour tissues were also selected for the 
immunohistochemical analysis of CXCL16 protein expression. The use of all tissue 
samples and patient data was approved by the NUS Institutional Review Board (NUS-
IRB Ref Code: 08-285, Approval Number: NUS 624). 
 
2.5.2 IMMUNOHISTOCHEMICAL ANALYSIS 
Serial sections of the aforementioned samples were immuno-stained to study 
the expression of trans-membrane CXCL16 using standard immunohistochemical 
techniques. Briefly, 4 µm-thick sections of formalin-fixed, paraffin-embedded tissues 
were de-paraffinized, and hydrated through several washes of Histoclear and graded 
alcohol respectively. Sections were then treated with hydrogen peroxide using 
Peroxidase Block (Envision+ DAKO Cytomation, Glostrup, Denmark) to quench 
endogenous peroxidase activity. Antigen retrieval was carried out by microwaving 
sections in pH 6 retrieval buffer (DAKO) for 20 minutes. Goat anti-human polyclonal 
primary antibody (R&D Systems) was added to sections thereafter and incubated for 
60 minutes at room temperature. After a complete wash, CXCL16-staining was 
detected using the DAKO Envision kit with polymer (K5007) with an incubation time 
of 30 minutes, followed by DAB staining for 10 minutes. Hematoxylin was used as a 
counterstain to stain cell nuclei. Finally, stained sections were dehydrated and 
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coverslips were mounted on sections. Sections were dried overnight and analysed via 
light microscopy.  
 
2.5.3 SCORING OF CXCL16 EXPRESSION IN IMMUNO-STAINED 
SECTIONS 
The scoring of CXCL16-stained samples was carried out according to the 
following parameters via light microscopy: 
1. Staining intensity as a measure of CXCL16 expression levels: from ‘+’ (low 
expression) to ‘+++’ (high expression). (Also referred to as parameter 1) 
2. Presence/absence of CXCL16-expressing (CXCL16-stained) or CXCL16-negative 
tumour infiltrating lymphocytes in tumour tissues. (Also referred to as parameter 2):  
A. Presence of CXCL16-expressing lymphocytes only (P) 
B. Presence of CXCL16-negative lymphocytes only (N) 
C. Presence of both CXCL16-negative and CXCL16-expressing lymphocytes (P/N) 
D. Absence of lymphocytes (Nil) 
All scoring results were verified by A/P Manual Salto-Tellez, pathologist at 
the Department of Physiology, Yong Loo Lin School of Medicine, National 
University of Singapore. 
 
2.5.4 CLINICOPATHOLOGICAL DATA ANALYSIS AND STATISTICS  
Upon scoring the CXCL16-stained tissues, two main statistical analyses were 
carried out. First, CXCL16 staining profiles (parameters 1 and 2 mentioned in section 
2.5.3) of normal and tumour TMAs were analysed separately to determine statistically 
significant differences in distribution of staining patterns between the normal and 
tumour TMAs. Thereafter, the collective CXCL16 staining patterns of epithelial cells 
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(parameter 1) and lymphocytes (parameter 2), was compared between normal and 
breast tumour TMAs. 
 Secondly an analysis to associate parameters 1 and 2 to clinicopathological 
data of patients was carried out. As indicated in section 2.5.1, patient data pertaining 
to tissue sections in the TMA was collated previously and kept as a database in the 
Department of Pathology, NUS for use with the TMA. The following analysis was 
carried out to determine associations between parameters (1) and/or (2) and patient 
data: 
A.  Association between parameter 1 and/or parameter 2 and lymph node metastases 
presence 
B. Association between parameter 1 and ER, PR and HER2 expression status 
A biostatistical analysis utilizing contingency table analysis and chi-square 
(χ2) tests to (a) determine the statistical significances of all comparisons of CXCL16 
staining intensity distribution data between normal and tumour TMA sections and to 
(b) determine the statistical significance of associations of CXCL16 staining intensity 
distribution data and the aforementioned clinocopathological data was carried out 
using the SPSS statistical software. 
 
2.6 CELL PROLIFERATION ASSAY 
An in-vitro Crystal Violet cell proliferation assay was utilized to determine the 
effect of CXCL16 treatment on cell proliferation. MCF-7 and MDA-MB-231 cells 
were seeded at a density of 2000 cells/well in 96-well plates. Separate plates were 
prepared for each time-point. Cells were allowed to equilibrate for 24hrs after plating. 
Thereafter cells were treated with 5ng/ml, 20ng/ml or 100ng/ml recombinant 
CXCL16 (n=6 for each concentration) and analysed at 2 time-points, namely 24hrs 
and 72hrs post-treatment. Control cells were left untreated. 
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At the respective time-points, cells were carefully washed twice in PBS and 
stained with Crystal Violet (C.V) solution, containing 0.5% w/v C.V, 8% v/v 
formaldehyde and 30% v/v absolute ethanol. After incubating for 10 minutes with 
C.V, the wells were washed again with ddH2O and 200µl of 1% SDS solution was 
added to each well to lyse the stained cells. Contents in each well were carefully 
mixed with gentle pipetting and the absorbance of C.V was read in a 
spectrophotometer with a 545nm wavelength filter. Absorbance values obtained were 
averaged for each treatment group at each time-point and converted as a percentage 
over the mean absorbance value of the untreated 24hr time-point. Differences in 
absorbance percentages, an indication of differences in cell proliferation, were noted 
between treated samples and untreated controls in the same time-points. 
 
2.7.1 SCRATCH-WOUND HEALING ASSAY 
An in-vitro scratch-wound healing assay was used to determine effects of 
CXCL16 treatment on cell migration. This scratch-wound assay is a well-
characterised in vitro assay that is commonly used to study the effects of drug 
treatments and gene alterations on cell motility and migration. It is also a viable 
method to study cell-cell interactions and cell-matrix interactions in an easy and 
replicable manner. The method utilized was according to recommendations by Liang 
et al (2007) (54). The experimental setup of this assay is as follows. All setups were 
maintained at 10% FBS throughout the experiments and scratch wounds were 
inflicted only when wells were fully confluent.  
MDA-MB-231 and MCF-7 cells were plated in 6-well culture plates at a 
density of 5x10
5
 cells/well (n=3) and treated with CXCL16 24 hours post plating. The 
cells were treated with CXCL16 prior to wound infliction to activate CXCL16-
mediated pathways in these cells so that potential changes to cell motility and 
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migration can be witnessed immediately after wound infliction. 24hrs after CXCL16 
treatment, a horizontal scratch wound was inflicted end-to-end centrally in each well 
with a standard p200 pipette yellow tip. This was done with a swipe across the well 
using the yellow tip. The removal of the strip of cells as a result produced an empty 
region i.e a ‘wound’ flanked by cells. Wells were washed once in PBS and twice in 
fresh media after wound infliction. Fresh media containing CXCL16 was reintroduced 
to pre-treated cells while untreated cells received fresh media only. 
To monitor the movement of cells (from the region flanking the wound) into 
the wound area, a spot was marked over a designated point at the wound area, on the 
plate cover over each well. Photographs at 100X magnification were taken at these 
marked spots with a light microscope (Zeiss Axiovert 40 CFL), at 0hr and 24hrs after 
wound infliction for MDA-MB-231 cell setups while MCF-7 cell setups were 
followed till the 48th hour. One photograph was taken at the marked spot for each 
sample at the required time-points to track the healing process. 
Because the healing patterns of MDA-MB-231 and MCF-7 cells were 
different, the numerical analysis of wound healing for both cell-types was assessed 
accordingly using an Imaging Program (Digimizer, MedCalc Software). The more 
epithelial-natured MCF-7 cells moved in a coordinated and close-knit manner into the 
wound area while the mesenchymal-like MDA-MB-231 cells moved individually into 
the wound area. As such, the extent of wound healing in the MCF-7 setups was 
determined by first demarking and calculating the total initial wound area inflicted 
(i.e. the whole wound area captured in the photographs) and then determining the 
unhealed wound area (i.e. area not closed up by cells) over the time-points by 
overlaying the initial demarked area into the images captured at the respective time-
points. All numerical values of areas were first determined in pixels before they were 
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converted to Unit Area using a Digimizer program feature (i.e using a conversion 
metric of total pixels per cm of screen image). All image analysis was scored 
consistently in the same personal computer. For the MCF-7 cells, since the cells 
moved in a close-knit manner into the wound and there were no empty spaces 
between the adjacent cells, the percentage of initial wound area healed at each time-
point was determined using the healed area (total initial area – unhealed wound area) 
over the initial wound area x 100%. For the MDA-MB-231 cells, the extent of wound 
healing at the 24hr time-point was determined by first counting the total number of 
cells that had infiltrated into the initial demarked wound area (determined similarly as 
in the MCF-7 setups) and then calculating the number of cells that were found in per 
Unit Area of the wound (i.e total number of cells in Wound Area/total Wound Area in 
Units).   
In addition, using this assay, we studied the effects of inhibiting the ERK 
signaling pathway in the MDA-MB-231 cells wound healing system, using a well-
known ERK signalling pathway inhibitor U0126. In separate wells, the scratch-wound 
assays were prepared as mentioned above. Upon scratch-wound infliction and PBS 
washes, either U0126 or CXCL16 and U0126 were added to these setups and the 
wound healing process was monitored for 24 hours after wound infliction.  
 
2.7.2 CONDITIONED MEDIA COLLECTION FROM CXCL16-TREATED 
AND UNTREATED WOUND HEALING ASSAYS AND TRANSFER TO 
FRESH SCRATCH-WOUND ASSAYS 
The ability of soluble factors released by CXCL16-treated MDA-MB-231 
cells in wound healing assays described above, to alter the wound healing rate of cells 
in fresh scratch-wound healing assays was assessed with the use of conditioned media 
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collected from CXCL16-treated and untreated wound healing assays. First, cells were 
seeded and pre-treated with CXCL16 or otherwise, as described above. After wound 
infliction, treated and untreated samples were washed thoroughly 3 times with PBS 
and once with fresh media before fresh media was added to samples once again.  
Conditioned media were collected from wound-healing assays 24 hours after wound 
infliction (n=3 each for CXCL16-treated and untreated samples) and spun down to 
separate cell debris from the conditioned media. All collected condition media were 
stored at -20°C until they were utilized for further experiments. 
Upon inflicting scratch-wounds in fresh assays (n=3 whereby one each for the 
conditioned media collected from the aforementioned biological triplicates), 
conditioned media from each of the prior experiment assays was mixed with fresh 
culture media in a ratio of 1ml conditioned media to 2 ml fresh media and added to 
the fresh scratch-wound assays. Wound healing was monitored again as described 
above for 24 hours after wound infliction.  
 
2.8 REAL-TIME PCR ARRAY ANALYSIS 
 To study the relative changes in gene expressions in our MDA-MB-231 
wound healing assays as a result of CXCL16 and/or U0126 treatment, a quantitative 
Real-Time PCR screening analysis was carried out with the aid of a Real-Time PCR 
array. 
 First, wound healing experiments with the following test conditions were 
carried out with the MDA-MB-231 cells, according to the procedures described in 
Section 2.7.1 and in biological duplicates:  
1. Assay with no scratch-wound and no treatments 
2. Assay with scratch-wound only and no treatments 
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3. Setup with scratch-wound and CXCL16 treatment 
4. Setup with scratch-wound and CXCL16 + U0126 treatments  
 At the end of 24 hours after wound infliction, cells from all setups were 
harvested by trypsinisation and washed with sterile PBS. Total RNA from cells was 
extracted and quantity/quality was determined as described in Section 2.3.  
 cDNA was synthesized from 1µg of total RNA from each of the 
aforementioned samples, with the RT
2
 First Strand Kit (C-03; SABiosciences 
Corporation), according to the manufacturer’s instructions. Gene expression analysis 
was carried out on a 96-well Human Tumor Metastasis RT² Profiler PCR Array 
(PAHS-028F-2, SABiosciences Corporation) featuring primers specific for 84 
metastasis-related genes (list of genes found in supplementary information section, 
Pg.105), according to the manufacturer’s instructions.  
Briefly, cDNA corresponding to 1µg of total RNA was mixed with Superarray 
RT² qPCR SYBR Green Master Mix 200 (PA-010; SABiosciences Corporation) and 
diluted further with ddH2O. 25µl of the mixture (containing cDNA corresponding to 
approximately 10.4ng of total RNA) was pipetted into each of the 96 wells with an 
eight-channel pipettor. Real-Time PCR was carried out on a Roche Lightcycler 480 
machine according to the parameters optimized and provided by SABiosciences 
Corporation. Cycle numbers of threshold fluorescence (Ct values) achieved after PCR 
amplification for each of the genes and controls were collated and loaded onto the 
analysis software provided by SABiosciences 
(http://www.sabiosciences.com/pcrarraydataanalysis.php) for relative gene expression 
fold change quantitation. Relative gene expression fold changes between the basal 
MDA-MB-231 gene expression levels (sample with no wound and treatments) and the 




relative fold change quantitation method. Where applicable, a change in gene 
expression of more than 1.5 fold was selected and classified as a significant fold 
change. All descriptions, symbols and functions of genes listed in this analysis were 
described by SABiosciences and are available online at 
http://www.sabiosciences.com. This information was also provided as technical 
information, upon purchase of the PCR Array from SABiosciences.  
 
2.9 TRANSWELL MIGRATION ASSAYS 
To determine if soluble CXCL16 is able to chemo-attract MDA-MB-231 cells, 
transwell migration assays were used to examine the migration of cells through 8µm 
polycarbonate transwell membranes in a polycarbonate transwell system (6.5mm 
insert, 24-well polystyrene plate configuration; Costar, Corning Inc). DMEM media 
containing 10% FBS was used in both the bottom and top chambers of the transwell. 
All experiment groups were assessed in triplicates (n=3 wells). In treated wells, 
100ng/ml of soluble CXCL16 was added to the bottom chamber of the transwell. 
First, media (containing CXCL16 or otherwise) was added to the bottom chamber and 
transwell membrane inserts (top chamber) were placed into the wells and equilibrated 
for 30 minutes. Thereafter, 4x10
4
 cells were seeded onto the membranes in the top 
chamber. Cells were then allowed to migrate from the top chamber through the 
membrane to the bottom chamber for 38 hours. All assays were maintained in the 
cell-culture incubator for that duration, after which the top chamber was removed and 
the migrated adherent cells in the bottom chamber were photographed at 100x 
magnification (note: 1 field image/well was captured centrally at midpoint of each 





2.10 STATISTICAL ANALYSIS 
Except for the  real-time PCR gene expression analysis results, where 
statistical analysis was not carried out since the experiments were done to screen for 
potential molecular interactions in the wound healing assays only, and the 
immunohistochemistry analysis results where a chi-square statistical analysis was 
carried out to determine statistical significances of differences in the respective 
distribution data, all experimental results were expressed as mean ± SEM and results 
were analysed for statistical significance by analysis of variance (ANOVA) tests. For 
these results, statistical significance was deduced when p≤0.05.    






























3.1 RT-PCR ANALYSIS OF CXCL16 AND CXCR6 EXPRESSIONS IN 
MAMMARY CELL-LINES 
As a preliminary analysis to profile CXCL16 and CXCR6 mRNA expression 
in mammary cell-lines, we determined through RT-PCR that CXCL16 and its receptor 
CXCR6 were expressed in one non-malignant breast cell-line (MCF10A), 1 pre-
malignant breast tumour cell-lines (MCF10AT1K) and 4 breast tumour cell-lines 
(MDA-MB-436, MDA-MB-231, MCF-7, HCC1937) (Fig 2). This indicated the 
presence of baseline CXCL16 and CXCR6 expression in breast cells. CXCL16 and 
CXCR6 protein expression profiles were not analysed in these cells in this study. 
CXCR6 expression was less prominent than CXCL16 expression in all cell-
lines, while CXCR6 expression in MCF10A and MCF10ATK1 was detected at trace 
levels. There were varying levels of CXCL16 and CXCR6 expression in the breast 
cancer cells, with the highest CXCL16 expression noted in the primary ductal 
carcinoma cell-line HCC1937 cells while the highest CXCR6 expression was noted in 
the highly metastatic MDA-MB-231 cell-line. Moreover, in this analysis involving the 
6 cell-lines, there was an apparent association between the metastatic potential of the 
cell-lines and CXCL16 expression levels. This was noted as a progressive decrease in 
CXCL16 expression from the primary ductal carcinoma cell-line HCC1937 to the 
poorly metastatic cell-line MCF-7 and then to the highly metastatic cell-lines MDA-
MB-436 and MDA-MB-231.  
Interestingly, between the cell-lines analysed, CXCR6 expression was highest 
in the highly metastatic MDA-MB-231 cell line while CXCL16 expression was the 
lowest in this cell-line. MDA-MB-231 cells could thus be highly responsive to soluble 
CXCL16-mediated molecular events and that CXCL16 could influence the manner in 
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which these breast cancer cells behave. Noting at the same time that MDA-MB-231 
cells are highly metastatic to the bone (58), which is a rich source of chemokines, we 






























Figure 2: CXCL16 and CXCR6 gene expressions in six human mammary cell-
lines 
CXCL16 and CXCR6 mRNA levels were analysed in non-malignant (MCF10A), pre-
malignant (MCF-10AT1K), high grade primary ductal carcinoma (HCC1937), highly 
metastatic (MDA-MB-436 & MDA-MB-231) and poorly metastatic (MCF-7) breast 
cell-lines by RT-PCR. The figure shows a general mRNA expression trend 
















































3.2 CXCL16 IMMUNOHISTOCHEMISTRY ANALYSIS OF BREAST 
NORMAL AND TUMOUR TISSUE SECTIONS  
In order to study the expression of CXCL16 at the protein level in breast 
tumours, an immunohistochemical analysis of CXCL16 expression in patient 
histological samples was carried out using tumour microarrays (TMA) consisting of 
97 patient tumour samples and a patient-matched TMA consisting 97 normal breast 
tissue sections as previously described (57). After the staining procedures, where we 
found that several sections were either mis-punched or lost, we were able to reliably 
analyse 27 normal and 84 tumour sections found in the TMA.    
We first undertook a qualitative preliminary analysis of CXCL16 expression 
in normal and tumour breast tissue full sections (Fig 3). As described earlier in Fig 1, 
CXCL16 is found in a cellular trans-membrane form and a cleaved soluble form that 
is derived only from the cleavage of the trans-membrane form. The soluble form is 
not known to be directly secreted from the cytosol. We first determined if our 
antibodies were staining for either or both of the trans-membrane and soluble 
CXCL16 forms in our tissue samples. From a qualitative standpoint, CXCL16 
staining in all our tissue samples appeared to be largely cellular and membraneous 
only (Fig 3). Thus we believe that the antibodies were predominantly staining for the 
expression of trans-membrane CXCL16 and not cleaved soluble CXCL16 in our 
TMA samples. Of note, it is unlikely that soluble CXCL16 would be retained for long 
at tumour sites once it is cleaved from trans-membrane CXCL16. It is thus probable 
that free cleaved soluble CXCL16 would either be released into the circulation, as 
shown previously in the case of pancreatic ductal adenocarcinoma (49), or 
metabolised by the system. Taking this information and our qualitative opinion into 
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account, we deduced that the CXCL16 expression seen in our tissue samples was that 
of the cellular trans-membrane form and not the cleaved soluble form. 
As seen in Figs. 3B and 3D, trans-membrane CXCL16 expression was seen in 
breast epithelial cells (labelled ‘N’ and ‘T’ in Figs 3B and 3D respectively) and some 
lymphocytes in the tumour tissues (Fig 3D). CXCL16 expression was not seen in the 
stromal tissue (labelled ‘S’) of both tumour and normal samples.  
Further to the observations above, we also found that there were varying 
intensities of CXCL16 staining in tumour and normal tissues found in the TMA and 
full tissue sections. As such, we classified the differential staining intensities on a 3-
point scale, with ‘+++’ staining being the highest expression intensity (Fig 4A and B) 
and ‘+’ being the lowest expression intensity (Fig 4C and D). As shown in Table 3, 
we noted a significant down-regulation of cellular trans-membrane CXCL16 in 
epithelial cells in a group of tumour tissues (p=0.004) found in the TMA. While 
70.4% of normal breast samples had ‘+++’ staining intensity, the tumour samples 
showed a marked reduction in “+++’ staining intensity (35.7% of cases) and a 
concomitant increase in ‘++’ (39.3%) and ‘+’ (25.0%) staining intensity. Thus cellular 
trans-membrane CXCL16 is down-regulated in breast tumour tissues as compared to 
normal breast tissues. 
In the case of the lymphocytes in the TMAs (Table 4), we found that the 
presence of lymphocytes was more evident in tumour tissues (69% of total cases) than 
normal tissues (22.2% of cases), which was not surprising, given that an 
immunological response directed at tumours is a common occurrence in many cases. 
Our analysis of the tumour infiltrating lymphocyte population revealed the presence 
of a sub-population of CXCL16-positive lymphocytes (P) (Fig 4E) and a sub-
population of CXCL16-negative lymphocytes (N) (Fig 4F). These lymphocytes 
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appeared to be residing next to the tumour mass. Moreover, only the CXCL16-
positive lymphocyte sub-population was detected in all of the normal breast tissue 
samples that revealed the presence of lymphocytes. In contrast, the inflammatory 
response in our tumour samples was significantly different (p<0.001). In these 
samples, we noted a mixture of both CXCL16-positive and negative sub-populations 
of lymphocytes in many cases, whereby the presence of the CXCL16-negative sub-
population was seen in 27 tissue samples as compared to 31 tissue samples that had 
CXCL16-positive lymphocytes only. Finally, in our tumour TMA samples, a trend 
was noted whereby the presence of CXCL16-negative lymphocytes increased with the 
loss of CXCL16 expression in these tumour samples (p=0.074; Table 5).  
We next determined if cellular trans-membrane CXCL16 expression was 
linked to the occurrence of lymph node metastasis. We noted a possible trend in our 
tumour TMA, showing an increase in lymph node metastasis occurrence with the 
down-regulation of cellular trans-membrane CXCL16 expression in tumour cells 
(Table 6), though this was not statistically significant (p=0.306). This is similar to the 
trend observed in our RT-PCR experiments where CXCL16 mRNA expression 
decreased as the metastatic potential of the cell lines analysed increased. Interestingly, 
we did not observe any trends linking lymphocytic CXCL16 expression and lymph 
node metastasis in these patients (p=0.817, Table 7). 
Finally, we observed a loss of ER expression with the down-regulation of 
epithelial trans-membrane CXCL16 expression from +++ intensity to ++ and + 
intensities (p=0.083) and a loss of PR expression with down-regulation of epithelial 
CXCL16 expression from +++ to ++ and + (p=0.044) (Table 8). Moreover, increased 
HER2 expression was noted with the steady down-regulation of epithelial CXCL16 
expression from +++ to + (p=0.083). These trends show a relationship between 
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epithelial trans-membrane CXCL16 expression and the expression of the 3 breast 
cancer-related markers whereby the down-regulation of cellular trans-membrane 
CXCL16 was associated with the down-regulation of ER, PR expression and up-














































































Figure 3: CXCL16 immunohistochemical staining of normal and tumour full 
histological sections 
The figures are representative images to show the general immunohistochemical 
staining patterns of CXCL16 in normal (A and B) and tumour (C and D) histological 
sections. Localised expression of CXCL16 was noted in normal breast epithelial (N) 
and breast tumour (T) cells. Normal epithelial cells making up the normal breast ducts 
(N) were stained more intensely than tumour cells (T) in many analysed samples. The 
stromal layer (S) did not stain positive for CXCL16, though there were CXCL16-
positive lymphocytes in the stroma in most tumour sections (black dots in Fig D). (E) 
CXCL16 antibodies were predominantly directed at cellular trans-membrane 
CXCL16 and not cleaved soluble CXCL16 and thus staining patterns were reflective 























































Figure 4: CXCL16 immunohistochemical staining of breast tumour tissue 
microarray (TMA) sections 
(A) CXCL16 staining of a tumour TMA section with high CXCL16 expression 
(‘+++’ intensity). (B) A magnified portion of the TMA section seen in (A). (C) 
CXCL16 staining of a tumour section with low CXCL16 expression (‘+’ intensity). 
(D) A magnified portion of the TMA section seen in (C). Presence of (E) CXCL16-
positive lymphocytes (unfilled block arrow pointing to dark spots) and/or (F) 
CXCL16-negative lymphocytes (black-filled block arrows pointing to blue spots) 
were noted in many TMA sections examined in the microarray. ‘S’ and ‘T’ indicate 



















Table 3: CXCL16 expression in breast epithelial tissue TMA 
sections  
  Normal TMA sections Tumour TMA sections 
Staining 
Intensity No. of sections % No. of sections % 
+ 1 3.7 21 25.0 
++ 7 25.9 33 39.3 
+++ 19 70.4 30 35.7 
Total 27 100.0 84 100.0 
    
    





Table 4: CXCL16 expression in lymphocytes present in TMA tissue sections 
     Normal TMA sections Tumour TMA sections 





NIL (no lymphocytes)      21 77.8 26 31.0 
CXCL16-positve 
lymphocytes only (P)   6 22.2 31 36.9 
CXCL16-negative 
lymphocytes only (N)   0 0.0 2 2.4 
CXCL16-positive and negative 
lymphocytes (P/N) 0 0.0 25 29.8 
Total: 27 100.0 84 100.0 
       
       





Table 5: Collective analysis of CXCL16 expression in breast epithelial cells and 
lymphocytes present in TMA sections 
Normal TMA sections Tumour TMA sections 
Lymphocytes status Lymphocytes status 
Epithelial cell 
staining 
intensity P/N P N NIL Total P/N P N NIL Total 
+++   3   16 19 5 15   10 30 
++   3   4 7 11 12   10 33 
+       1 1 9 4 2 6 21 
Total 0 6 0 21 27 25 31 2 26 84 













Table 6: CXCL16 expression in tumour TMA sections and 
lymph node metastases occurrence 
 Lymph node metastasis 
Intensity + - NA Total % + 
+++ 11 19 0 30 36.7 
++ 16 16 1 33 48.5 
+ 11 9 1 21 52.4 
Total 38 44 2 84 45.2 
     
p=0.386 (CXCL16 
expression intensity 




Table 7: Lymphocyte CXCL16 expression in tumour TMA sections and lymph 
node metastases occurrence 
          Lymph node metastasis 
Tissues with:       + - NA Total % + 
NIL (no lymphocytes):      12 13 1 26 46.2 
CXCL-16 positve lymphocytes only 
(P):   14 17 0 31 45.2 
CXCL-16 negative lymphocytes 
only (N):   0 1 1 2 0.0 
CXCL-16 positive and negative 
lymphocytes (P/N): 12 13 0 25 48.0 
Total: 38 44 2 84 45.2 









Table 8: CXCL16, ER, PR and HER2 expressions in tumour TMA sections  
Intensity ER+ ER- 
% 









+++ 23 7 76.7 22 8 73.3 11 18 1 37.9 
++ 17 16 51.5 14 19 42.4 18 15  54.5 
+ 11 10 52.4 11 10 52.4 14 6 1 70.0 








p=0.083 (CXCL16 expression 










3.3 EFFECT OF SOLUBLE CXCL16 ON MDA-MB-231 AND MCF-7 CELL 
PROLIFERATION  
 To determine if soluble CXCL16 treatment alters one or both of MDA-MB-
231 and MCF-7 cell proliferation, these cells were treated with varying dosages of 
CXCL16, including a high dosage of 100ng/ml, for up to 72 hours. A crystal violet 
cell proliferation assay was used as a surrogate measure of cell number. As indicated 
in Fig 5, there was no significant difference in crystal violet absorbance between the 
untreated and treated samples for both cell-lines, across 72 hours post-CXCL16 
treatment. Utilising a similar experimental setup with another cell proliferation assay, 
the WST-1 cell proliferation assay, preliminary results also produced similar results to 
that of the crystal violet assay (results not shown). Soluble CXCL16 thus did not 
appear to alter cell proliferation in both the highly metastatic MDA-MB-231 and 

































Figure 5: Effect of soluble CXCL16 on MCF-7 and MDA-MB-231 cell 
proliferation 
Cell proliferation after soluble recombinant human CXCL16 treatment was 
determined over a time period of 72 hours in (A) MCF-7 and (B) MDA-MB-231 cell 
setups (n=6 per treatment group). Cell proliferation in each treatment group for the 
respective cell-lines is determined as percentage mean absorbance of crystal violet 
incorporated into viable cells in treated samples vs untreated samples. All experiments 
were repeated 3 times with similar results and the results above are from one of these 
experiments. Error bars indicate the ±SEM (n=6 setups per treatment group) in mean 





























































Effect of soluble CXCL16 on MCF-7 cell 
proliferation as measured by crystal violet 













































Effect of soluble CXCL16 on MDA-MB-231 cell 
proliferation as measured by crystal violet cell 
proliferation assay 
Time after treatment 
(hrs) 
24hr 72hr 











3.4 EFFECT OF SOLUBLE CXCL16 ON MDA-MB-231 AND MCF-7 CELL 
MIGRATION 
We determined the effects of soluble CXCL16 on breast cancer cell migration 
using the scratch-wound healing assay. With this assay, the closure of the scratch 
wound was monitored by analysing the movement of cells into the wound area. In the 
presence of various treatments (CXCL16 and/or U0126) the rate of wound closure 
and movement of cells into the wound were used as measures to determine cell 
migration after these treatments. 
As seen in Figure 6 and Figure 9, the healing patterns of MDA-MB-231 and 
MCF-7 cells respectively were different and thus our numerical analysis of wound 
healing for both cell-types had to also differ accordingly. The more epithelial-natured 
MCF-7 cells moved in a coordinated and close-knit manner into the wound area while 
the mesenchymal-like MDA-MB-231 cells moved individually into the wound area. 
As such, we determined the extent of wound healing in the MCF-7 setups by 
determining the percentage of initial wound area healed, since the cells moved in a 
close-knit manner into the wound and there were no empty spaces between the 
adjacent cells. For the MDA-MB-231 cells, we determined the extent of wound 
healing by counting the number of cells that had infiltrated into the initial wound area 
and calculating the number of cells found in per unit area of the wound.  
We observed in our wound-healing model that soluble CXCL16 treatment 
(100ng/ml) significantly increased (p<0.001 vs untreated controls) wound-healing in 
both the MDA-MB-231 (Figure 7) and MCF-7 setups (Figure 10). The increase was 
more prominent in the MDA-MB-231 setups, where the number of cells that 
infiltrated the wound 24hrs after wound infliction was about 2.5 folds more in the 
CXCL16-treated samples than the untreated controls. This increase however was 
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reversed in setups incorporating both CXCL16 and U0126 treatment. This provided 
first evidence that soluble CXCL16 treatment positively altered the migratory 
potential of both breast cancer cell types. Since U0126 treatment was able to reverse 
this effect, it was evident that the ERK pathway was critical to the entire healing 
process and that CXCL16-mediated increase in cell migratory capability was perhaps 
not independent of this pathway. Moreover, CXCL16-influenced cell migration 
increase could have also been a result of either a direct action of CXCL16 on the ERK 
pathway or through an indirect mediator that could activate ERK. 
Taking into account that soluble CXCL16 treatment does not alter cell 
proliferation (Figure 5), these observations suggest that the differences in cell 
numbers were most likely due to the difference in the number of cells that migrated 
into the wound. These results thus support our hypothesis that soluble CXCL16 plays 
a role in increasing breast cancer cell motility and cell migration.   
In order to further determine if the chemotactic response of cells to soluble 
CXCL16 could also increase the migratory potential of cells, we observed through a 
transwell migration assay (Figure 7C) that more MDA-MB-231 cells migrated from 
the top chamber of wells to the bottom chamber containing soluble CXCL16 as 
opposed to those wells with soluble CXCL16 absent from the bottom chamber 
(p<0.001 vs untreated controls). Thus, soluble CXCL16 possibly exerts a chemotactic 
effect on CXCR6-expressing breast cancer cells that possess a functional CXCL16-
CXCR6 signalling mechanism.  
Using conditioned media (CM) from CXCL16-treated wound-healing setups 
and untreated setups, preliminary experiments have shown that the increased 
migratory potential observed in the CXCL16-treated wound healing assays (Figure 
7B) could also be carried forward to fresh, untreated wound-healing setups  (Figure 
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8). This resulted in a statistically significant increase (p<0.001 vs setups with CM 
from untreated wound healing samples) in cell migration between the samples treated 
with CM from CXCL16-treated samples and samples treated with CM from untreated 
samples. Because the scratch-wound wells were thoroughly washed before fresh 
media were added to the wells and incubated for 24hrs prior to collection of CM, it is 
highly unlikely that the effects seen in setups treated with CM collected from 
CXCL16-treated samples were due to residual CXCL16 found in the CM. This 
indicates that soluble CXCL16 treatment may program cells to release certain soluble 
factors that potentially increase cancer cell migratory abilities. Consequently, this 



































































Figure 6: Effects of CXCL16 and/or U0126 treatment on wound healing in 
MDA-MB-231 cells wound healing assays 
Wound healing was observed and analysed in untreated (A and B), CXCL16-treated 
(C and D), CXCL16 and U0126-treated (E and F) and U0126-treated (G and H) 
samples over a time-span of 24 hours. Images on the left panel (A, C, E and G) were 
captured immediately after wound infliction (0hr) while images on the right panel (B, 
D, F and H) were captured 24 hours after wound infliction (24hr) at the same spot as 
that at 0hr. Solid horizontal lines in each image demarcate the edge of the initial 
scratch-wound. Images are representative of general trends observed in 3 separate 





















Figure 7: Numerical analysis of wound healing and transwell migration assays in 
MDA-MB-231 setups 
(A). Mean wound area of wound healing assays utilised for experiments in Figure 6. 
Experiments were repeated 3 times with similar results and data presented is from one 
of these experiments. Error bars indicate ±SEM in mean wound areas used in the 
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area of the wound analysed in the respective assays seen in Figure 7A, 24 hours after 
wound infliction. Error bars indicate the ±SEM in mean number of cells/unit wound 
area (n=3 per treatment). ‘+++’ indicates p<0.001 vs untreated controls while ‘***’ 
indicates p<0.001 vs CXCL16-treated samples only. The error bars in many instances 
are small with a sample number of n=3. (C). Mean number of migrated cells at the 
bottom chamber of transwell migration assays (n=3), determined through a manual 
count of cells in the bottom chamber of each transwell at 100x magnification. 
Experiments were repeated twice with consistent results and results shown are from 
one of these experiments. Error bars indicate the ±SEM in the mean number of cells 
that have migrated to the bottom chamber in the assays (n=3 setups). ‘+++’ indicate 
p<0.001 vs untreated controls.  
 
 
Figure 8: Numerical analysis of fresh MDA-MB-231 wound healing assays 
carried out with conditioned media (CM) collected from CXCL16-treated and 
untreated MDA-MB-231 wound healing assays 
(A). Mean wound area of wound healing assays utilised for experiments using 
conditioned media (CM) collected from CXCL16-treated and untreated wound 
healing assays. Experiments were repeated twice with similar results and data 
presented is from one of these experiments. Error bars indicate ±SEM in mean wound 
areas used in the respective assays (n=3 per treatment). (B). Mean number of cells 
found in per unit area of the wound analysed in the respective assays seen in Fig 8A, 
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cells/unit wound area (n=3 per treatment). ‘+++’ indicates p<0.001 vs untreated CM 





























Figure 9: Effects of CXCL16 and/or U0126 treatment on wound healing in MCF-
7 cells wound healing assays 
Wound healing was observed and analysed in untreated (A-C), CXCL16-treated (D-
F), CXCL16 and U0126-treated (G-I) and U0126-treated (J-L) samples over a time-
span of 48 hours. Images on the left panel (A, D, G and J) were captured immediately 
after wound infliction (0hr), images in the middle panel (B, E, H and K) were 
captured 24 hours after wound infliction (24hr) and images on the right panel (C, F, I 
and L) were captured 48 hours after wound infliction (48hr) at the same spot as that at 
0hr. Solid lines in each image demarcate the edge of the scratch-wound. Images are 
representative of general trends observed in 3 separate repeat experiments (n=3 per 

























































Figure 10: Numerical analysis of wound healing assays in MCF-7 setups 
(A). Mean wound area of wound healing assays utilised for experiments in Figure 9. 
Experiments were repeated 3 times with similar results and data presented is from one 
of these experiments. Error bars indicate ±SEM in mean wound areas used in the 
respective treatments (n=3 per treatment). (B). Mean wound area healed in the 
respective assays seen in Figure 10A, 24hrs and 48hrs after wound infliction. Error 
bars indicate the ±SEM in the percentage of mean wound area healed for the 
respective treatments (n=3 per treatment). ‘+++’ indicates p<0.001 vs untreated 
controls while ‘***’ indicates p<0.001 vs CXCL16-treated samples only. The error 
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3.5 REAL-TIME PCR ARRAY ANALYSIS  
In order to elucidate molecular mechanisms that could explain the increased 
cell migratory capabilities conferred by CXCL16 and the attenuation of that effect by 
the ERK inhibitor U0126, we screened for relative gene expression changes as a result 
of the respective treatments in a Real-Time PCR array of 84 genes that have been 
implicated previously in cancer metastasis. Our main aim was to find candidate genes 
whose expressions were altered upon scratch-injury infliction, CXCL16 treatment and 
ERK pathway inhibition by U0126, and thereby explain the observations seen in our 
scratch-wound assay experiments. We were mindful though of the fact that the mere 
alteration of several gene expressions seen in this screening experiment may not 
conclusively explain the observations seen in our wound healing assays. However, as 
this was a screening experiment, our objective was to obtain a shortlist of candidate 
genes that we could validate later in follow-up studies for mechanistic or functional 
relevance. 
The overall relative gene expression fold differences across the panel of 84 
genes, seen as a result of the different test conditions and treatments, are detailed in 
Supplementary Results Attachment 1 (attached in the supplementary information 
section Pg.80). For the purpose of this analysis, we deduced an expression fold 
change of at least 1.5 fold as a notable gene expression difference between the 
examined test conditions and treatments. These fold differences in gene expression 
are listed in Tables 9-15 for focused comparative analysis. As shown in these Tables, 
our main focus was on the following test conditions: (a) gene expression differences 
as a result of wound infliction in untreated cell setups (Table 9), (b) expression 
differences between CXCL16-treated wound samples and untreated wound samples 
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(Table 10), (c) expression differences between CXCL16-treated wound samples and 
untreated, unwounded samples (basal expression levels in MDA-MB-231 cells) 
(Table 11), (d) expression differences between CXCL16 + U0126-treated samples and 
CXCL16-treated wound samples (Tables 12 and 13) and (e) expression differences 
between CXCL16 + U0126-treated samples and untreated, unwounded samples 
(Tables 14 and 15).   
We found that the expression of only 2 genes: Matrix Metalloproteinase 13 
(MMP13) (+1.94 fold difference) and Somatostatin Receptor 2 (SSTR2) (+2.04 fold 
difference), were significantly up-regulated solely as a result of wound infliction 
(Table 9) while no genes were significantly down-regulated as a result of wound 
infliction. Of these two genes, only SSTR2 expression was down-regulated 
significantly (by 1.9 fold) in CXCL16-treated wound sample when compared to the 
untreated wound samples (Table 10). There was very slight change to MMP13 
expression in the CXCL16-treated wound samples. It thus appeared that the 
expression of SSTR2 was in some way linked to the CXCL16 signalling pathway. 
Similarly, another gene that appeared to be down-regulated in the CXCL16-treated 
wound samples was the transcription factor Nuclear Receptor subfamily 4, group A, 
member 3 (NR4A3) (by 1.79 fold; Table 10). Notably, this gene was also slightly (but 
not significantly) up-regulated upon wound infliction in untreated samples (by 1.24 
fold; Supplementary Results Attachment 1). No genes were up-regulated significantly 
in the CXCL16-treated wound samples as compared to the untreated wound samples. 
Thus it appeared that both SSTR2 and NR4A3 could be regulated by the CXCL16 
signalling pathway. 
In addition, we analysed gene expression differences between CXCL16-
treated wound samples and the basal gene expression levels of MDA-MB-231 cells 
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(Table 11) to determine the extent to which expression profiles differed between the 
CXCL16-treated wound samples and the initial basal expression levels. Unlike the 
previous analysis, where we dissected the process to determine genes changed as a 
result of wound infliction and genes regulated by CXCL16 in wounded samples, this 
was somewhat a cumulative analysis to view the extent to which the expression of 
genes were altered with regards to basal levels. In this analysis, we found only 2 
genes that were significantly up-regulated in the CXCL16-treated wound samples as 
compared to the basal levels: MMP13 (by 1.88 fold) and MMP9 (by 1.69 fold). No 
genes were found to be significantly down-regulated in this case. As seen earlier, the 
expression of MMP13 increased right from the point of wound infliction and was only 
marginally reduced by CXCL16 treatment. However, SSTR2 expression was first 
increased by wound infliction and then brought back to the basal levels by the 
CXCL16 signalling pathway (Supplementary Results Attachment 1) in the CXCL16-
treated wound samples. In the case of NR4A3, which we deduced above as a 
candidate gene possibly regulated by CXCL16, the overall change in expression with 
regards to basal expression levels was a reduction of about 1.45 fold (Supplementary 
Results Attachment 1). In the case of MMP9 the expression level was increased after 
wound infliction by 1.28 fold and then again after CXCL16 treatment by 1.26 fold. 
Thus, while the difference in expression level with regards to basal levels was 
significant, the increases at the individual stages were insignificant. However, even 
though the regulation of MMP9 by CXCL16 was not significant, it is possible that the 
up-regulation of MMP9 by CXCL16 after wound infliction could still be contributing 
to the increased migratory potential of cells treated with CXCL16.   
Our final set of analysis focused on genes that were down-regulated as a result 
of U0126 treatment and ERK pathway inhibition. When the gene expression profiles 
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of U0126 and CXCL16-treated wound samples were compared to that of the 
CXCL16-treated wound samples, we found that ERK inhibition increased the 
expression of 6 genes (Table 12) and decreased the expression of 21 genes (Table 13) 
by at least 1.5 fold. Of these genes, the expressions of SSTR2, MMP13 and NR4A3 
were once again up-regulated by 1.73 fold, 1.88 fold and 2.38 fold respectively. Two 
other MMPs, MMP11 and MMP7 were also up-regulated, with MMP7 showing a 
highly significant up-regulation of about 6 fold. Of note, the expression of MMP9 
which first increased after wound infliction and further up-regulated after CXCL16 
treatment, was also down-regulated after ERK inhibition by 1.48 fold (Supplementary 
Results Attachment 1). The most significant down-regulation was in the expression of 
the transcription factor ETV4 (by 22.5 fold), whose expression is critically controlled 
by the ERK pathway.  
When the gene expression profiles of U0126 and CXCL16-treated wound 
samples were compared to basal gene expression levels (Table 14), 5 of the 6 genes 
found to be up-regulated above (Table 12) were also found to be up-regulated when 
compared to basal expression levels. This again included SSTR2 (by 1.77 fold), 
NR4A3 (by 1.64 fold) and MMP13 (by 3.53 fold). Moreover, 22 genes were found to 
be down-regulated when compared to basal expression level (Table 15). We had 
noted earlier that only the expression of 2 genes, MMP13 and MMP9, were increased 
when the gene expression of CXCL16-treated wound samples were compared to basal 
expression levels (Table 11). Here, the elevated expression of MMP9 was reduced to 
basal levels upon U0126 treatment (Supplementary Results Attachment 1) while the 
expression of MMP13 increased further. This analysis thus provided us with an 
insight and overall picture of the extent to which the genetic profile of the CXCL16 + 
U0126-treated MDA-MB-231 cells in the wound samples had changed with regards 
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to the initial basal genetic profile of the cells. Such changes would provide a snapshot 
to explain potential differences in behaviour of the treated/wounded cells in relation to 
the initial untreated/unwounded cells, for example (this in itself is a control). 
Additionally, it will also allow us to compare the differences in gene expression 
resulting from the various manipulations (i.e. treatments, wounding, etc) against this 
overall picture, so that appropriate candidate genes could be deciphered to describe 
the healing behaviours seen in the wound healing assays.        
Thus when we reconciled the wound healing assay results and the gene 
expression analysis results, we found that the expression of 3 genes out of the panel of 
84, namely, SSTR2, MMP13 and NR4A3 were regulated sequentially and somewhat 
prominently at all the test conditions mentioned above (Figure 11). These candidate 
genes are of particular interest for follow-up analysis. Upon scratch-wound infliction, 
SSTR2 and MMP13 expressions were significantly up-regulated. The significant 
down-regulation of SSTR2 and NR4A3 in the CXCL16-treated wound setups as 
compared to the untreated wound setups was associated with the increased wound 
healing witnessed in CXCL16-treated wound healing setups. Next, upon ERK 
inhibition where the CXCL16-induced increase in cell motility was reversed, the 
expressions of SSTR2, NR4A3 and MMP13 were concomitantly and significantly 
increased.  
The trend of MMP9 expression is also interesting since MMP9 expression was 
first increased after injury infliction and then again as a result of CXCL16 treatment 
but reduced to basal levels after U0126 treatment. As such determining the functional 
relevance of MMP9 in CXCL16-induced increase in cell motility would also be an 
interesting follow-up. Finally, all the genes that are regulated by the ERK pathway 
(i.e. affected by U0126) are potential individual downstream targets that could reverse 
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the CXCL16-mediated cell migration increase witnessed in our experiments, to a 
similar manner as the ERK inhibitor U0126, without having to regulate the ERK 
pathway per se. These genes were thus valid targets for further analysis. 
Our screening results suggested that there was a down-regulation of SSTR2 
upon CXCL16 stimulation and this decrease was reversed by U0126 treatment. 
Because SSTR2 is believed to mediate anti-tumour effects (59) and the results 
suggested that it may be either directly or indirectly regulated by CXCL16 and the 
ERK pathway, we speculated that the increase in cell migration as a result of 
CXCL16 treatment could be due to the down-regulation of SSTR2 receptor 
expression and the eventual reduction in somatostatin signalling.   
We thus determined if SSTR2 had functional relevance in the context of our 
wound-healing model by inhibiting SSTR2 function with a SSTR2-selective inhibitor, 
CYANAMID. SSTR2 inhibition on its own increased cell migration in our wound 
healing assay, albeit to a lesser extent than CXCL16 but it did not cause any visible 
changes to cell migration when added to setups containing both CXCL16 and U0126 
(i.e it did not counter-reverse U0126-mediated cell-migration decrease in CXCL16-
treated samples) (results not shown). Thus in the context of CXCL16 and our wound 
healing assay, SSTR2, which was one of our 3 candidates genes picked to test for 
functional relevance with regards to the observations seen in our wound healing 






















Table 9: Gene expression up-regulation after wound infliction in untreated  






Somatostatin receptor 2 SSTR2 2.04 Cell growth and proliferation 




Table 10: Gene expression down-regulation in CXCL16-treated wound setups 






Nuclear receptor subfamily 4, 
group A, member 3 
NR4A3 1.79 
Cell growth and proliferation; 
transcription factor 




Table 11: Gene expression up-regulation in CXCL16-treated wound setups vs 






Matrix Metallopeptidase 9 MMP9 1.88 Extracellular matrix protein 






















Table 12: Gene expression up-regulation in CXCL16 and U0126-treated wound 






Fibroblast growth factor 
receptor 4 
FGFR4 1.73 Cell growth and proliferation 
Nuclear receptor subfamily 4, 
group A, member 3 
NR4A3 2.38 
Cell growth and proliferation; 
transcription factor 
Somatostatin receptor 2 SSTR2 1.73 Cell growth and proliferation 
Matrix Metallopeptidase 11 MMP11 1.78 Extracellular matrix protein 
Matrix Metallopeptidase 13 MMP13 1.88 Extracellular matrix protein 
Matrix Metallopeptidase 7 MMP7 5.90 Extracellular matrix protein 
 
Table 13: Gene expression down-regulation in CXCL16 and U0126-treated 






Collagen, type IV, alpha 2 COL4A2 1.65 Extracellular matrix protein 




Cell growth and 
proliferation; apoptosis 
C-X-C Chemokine Receptor 4 CXCR4 5.66 
Cell growth and 
proliferation; apoptosis 
Gonadotropin-releasing hormone 
1 (luteinizing-releasing hormone) 
GNRH1 1.55 
Cell growth and 
proliferation 
Plasminogen activator, urokinase 
receptor 
PLAUR 1.51 
Cell growth and 
proliferation 
Met proto-oncogene (hepatocyte 
growth factor receptor) 
MET 2.07 
Cell growth and 
proliferation 
V-Ha-ras Harvey rat sarcoma viral 
oncogene homolog 
HRAS 1.77 
Cell growth and 
proliferation; cell cycle 
Protein (NM23A) expressed in 
non-metastatic cells 1 
NME1 1.99 
Cell growth and 
proliferation; cell cycle 
Metastasis suppressor 1 MTSS1 2.09 Cell adhesion; cell cycle 
Cadherin 11, type 2, K-cadherin 
OB-cadherin (osteoblast) 
CDH11 1.74 Cell adhesion 
FAT tumour supressor homolog 1 
(Drosophila) 
FAT 1.51 Cell adhesion 
Retinoblastoma 1  RB1 1.63 
Transcription factor; cell 
cycle 
Ets variant gene 4 (E1A enhancer 
binding protein, E1AF) 
ETV4 22.50 Transcription factor  
Cystatin F (leukocystatin) CST7 2.33 Others 
Methionyl aminopeptidase 2 METAP2 1.51 Others 
Protein expressed in non-
metastatic cells 4 
NME4 1.89 Others 
CD 82 molecule CD82 4.28 Others 
KiSS-1 metastasis-suppressor KISS1 2.30 Others 
Hypoxanthine 
phosphoribosyltransferase 1 
HPRT1 1.95 Internal control gene 
Glyceraldyhyde-3-phosphate 
dehydrogenase 




Table 15: Gene expression down-regulation in CXCL16 and U0126-treated 






Collagen, type IV, alpha 2 COL4A2 1.62 
Extracellular matrix 
protein 




inducing factor) IL18 1.75 
Cell growth and 
proliferation; apoptosis 
C-X-C Chemokine Receptor 4 CXCR4 5.25 
Cell growth and 
proliferation; apoptosis 
Tumour necrosis factor (ligand) 
superfamily, member 10 
TNFSF1
0 1.56 Apoptosis 
Gonadotropin-releasing hormone 1 
(luteinizing-releasing hormone) GNRH1 2.00 
Cell growth and 
proliferation 
Plasminogen activator, urokinase 
receptor PLAUR 1.54 
Cell growth and 
proliferation 
Met proto-oncogene (hepatocyte 
growth factor receptor) MET 1.96 
Cell growth and 
proliferation 
V-Ha-ras Harvey rat sarcoma viral 
oncogene homolog HRAS 1.51 
Cell growth and 
proliferation; cell cycle 
Protein (NM23A) expressed in 
non-metastatic cells 1 NME1 1.86 
Cell growth and 
proliferation; cell cycle 
Metastasis suppressor 1 MTSS1 2.83 Cell adhesion; cell cycle 
Cadherin 11, type 2, K-cadherin 
OB-cadherin (osteoblast) CDH11 1.69 Cell adhesion 
Fibronectin 1 FN1 1.51 Cell adhesion 
Acetyl-glucosaminyltransferase V MGAT5 1.52 Cell adhesion 
Integrin, Beta 3 ITGB3 1.66 Cell adhesion 
Retinoblastoma 1  RB1 1.66 
Transcription factor; cell 
cycle 
Ets variant gene 4 (E1A enhancer 
binding protein, E1AF) ETV4 23.56 Transcription factor  
Cystatin F (leukocystatin) CST7 2.00 Others 
Protein expressed in non-
metastatic cells 4 NME4 1.52 Others 
CD 82 molecule CD82 4.24 Others 
KiSS-1 metastasis-suppressor KISS1 2.12 Others 
Hypoxanthine 
phosphoribosyltransferase 1 HPRT1 1.98 Internal control gene 
Table 14: Gene expression up-regulation in CXCL16 and U0126-treated wound 






Matrix Metallopeptidase 11 MMP11 1.81 Extracellular matrix protein 
Matrix Metallopeptidase 13 MMP13 3.53 Extracellular matrix protein 
Matrix Metallopeptidase 7 MMP7 5.40 Extracellular matrix protein 
Nuclear receptor subfamily 
4, group A, member 3 NR4A3 1.64 
Cell growth and proliferation; 
transcription factor 
























Figure 11: MMP13, SSTR2 and NR4A3 gene expression trends observed after 
wound infliction and treatments   
MMP13, SSTR2 and NR4A3 gene expression trends across 4 test conditions, as 
determined by SYBR Green real-time PCR. These 3 genes were selected from a PCR 
array screening experiment (n=2 per test condition) that was executed to pick 
candidate genes that could be implicated with the trends observed in the wound-
healing assays (test conditions in graph). They were the only genes out of a possible 
84 cancer metastasis-related genes that demonstrated a prominent trend in expression 
across all the four test conditions depicted in the graph above. The graph highlights a 
common average expression trend (n=2 setups) by the 3 genes whereby the increase 
in gene expression after one test condition (e.g unwounded + untreated) would be 
followed by a subsequent decrease in expression at the next test condition (e.g 







































































































































4. DISCUSSION AND CONCLUSION 
4.1 CXCL16 EXPRESSION ANALYSIS IN BREAST CANCER CELL-LINES 
AND PATIENT HISTOLOGICAL SAMPLES 
In this study, we endeavoured to elucidate the potential roles of chemokine 
CXCL16 in mediating breast cancer tumourigenesis and metastasis. Particular 
importance was given to determining the effects of soluble CXCL16 on breast cancer 
cell migration in vitro. Cell migration is an important aspect of cancer metastasis and 
is believed to be the first step in the establishment of tumours at distant sites. 
Typically, cancer cells invade the surrounding tissues of the primary site (cell 
migration) and enter either the lymphatic or blood circulation (also known as 
intravasation), where they travel to their secondary site. When these sites are reached, 
the cells breach the transporting vessel’s wall (also known as extravasation) and enter 
their new site, where they once again migrate to their preferred location and colonize 
with the aid of a network of blood vessels that nourish these cells. This eventually 
leads to the establishment of a secondary tumour site (metastases) (60).  
This is an important study since many of the data on the role of CXCL16 on 
breast cancer to-date has been conflicting, confusing and inconclusive. Thus more 
work is required to decipher the roles both forms of CXCL16 played in the context of 
tumourigenesis and metastasis. In this study, we attempted to elucidate several novel 
roles of CXCL16 in the pathogenesis of breast cancer, particularly in the context of 
breast cancer cell migration.   
Our CXCL16 expression analysis data on both patient histological samples 
and cell-lines have clearly given us grounds to suggest that CXCL16 is expressed in 
normal breast and breast cancer tissue. This observation is contrary to the 
observations of Meijer et al (2008) (19), who have suggested that CXCL16 expression 
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is tumour-specific. Because Meijer and colleagues have based their observations of 
CXCL16 expression on a murine normal epithelial cell-line, it is possible that the 
expression of CXCL16 may be species specific. In our analysis, we utilised adjacent-
to-tumour normal breast tissue samples to analyze CXCL16 expression in normal 
tissues. While these may not be ‘truly’ normal, the expression of CXCL16 in the 
MCF10A normal human breast cell-line is suggestive enough for us to believe that 
CXCL16 expression is found in both normal and tumour breast tissue.  
To our knowledge, our immunohistochemistry analysis is also the first 
comprehensive attempt at characterising CXCL16 expression in both normal and 
tumour breast patient samples. Through this analysis, we have elucidated that the 
expression of cellular trans-membrane CXCL16 in the breast tumour 
microenvironment is evident in not only the tumour cells but also in the infiltrating 
lymphocytes that invade the tumour microenvironment. Thus both CXCL16 positive 
tumour cells as well as CXCL16-expressing lymphocytes could be acting together (or 
independently) to influence and modulate the tumour microenvironment via CXCL16 
signalling pathways. In our study, it is unclear how the presence of CXCL16-positive 
and negative lymphocytes affects the behaviour of tumour cells. Moreover, we are 
unable to ascertain the relevance of the CXCLl6-negative lymphocytes that seem to 
be readily recruited in inflammatory responses seen in our tumour tissues as opposed 
to our normal tissues. This observation thus warrants further analysis. 
Indeed, our observation of CXCL16-positive lymphocytes at tumour sites is a 
novel finding, noting that there are no clear reports describing the presence of 
CXCL16-positive lymphocytes in any context. It is possible though that these 
lymphocytes could also be present in several contexts, such as in Rheumatoid 
Aarthritis (RA) and cancers, but were not characterised since the importance of this 
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subset of lymphocytes in inflammatory responses were not studied specifically. For 
example, it has been previously shown that CXCL16/CXCR6 signalling pathway has 
a pathogenic role in RA (61), through the interaction of CXCL16 expressed in the RA 
synovium and CXCR6 expressed in the synovial T cells. It is possible that the 
presence of CXCL16-positive lymphocytes in this T cell pool, if any, may be 
influencing the progression of RA in this scenario. These speculations should be 
analysed further. Moreover, while the presence of CXCR6+ lymphocytes has already 
been analysed in several contexts (11, 17, 20-24), it would be worthwhile in future 
studies to specifically analyse the proportion of CXCL16-positive and negative 
lymphocytes in this subset of CXCR6+ lymphocytes so as to understand how these 
subsets of lymphocytes affect the behaviour of tumours and their microenvironment. 
In our histological analysis, the CXCL16-positive lymphocytes in tumour tissues were 
mainly found at the tumour-stromal interface and these lymphocytes seemed to be 
interacting with the tumour mass. This interaction could possibly take place through 
mechanisms governed by trans-membrane CXCL16 (interaction between CXCR6 
found in tumour cells and trans-membrane CXCL16 found in lymphocytes) and/or 
soluble CXCL16 associated signalling mechanisms. These interactions presumably 
add to other signalling mechanisms that ‘educate’ tumour cells to acquire a more 
metastatic phenotype. 
From our study, we can clearly conclude that there is a statistically significant 
loss of cellular trans-membrane CXCL16 expression at the protein level in breast 
tumour tissue samples as compared to normal breast tissue samples. Our data has also 
revealed a trend that suggests that the down-regulation of cellular trans-membrane 
CXCL16 in tumours could be linked to a higher incidence of lymph node metastasis 
(though this is a statistically insignificant trend and perhaps more samples need to be 
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analysed to verify this aspect) (Table 6). It is possible that this down-regulation could 
be mediated in two ways. First, the shedding of cellular trans-membrane CXCL16 to 
the cleaved soluble form by ADAMs could be one mechanism through which trans-
membrane CXCL16 is down-regulated in tumours.  
The second way through which the tumour tissues could reduce CXCL16 
expression is by down-regulating the expression of CXCL16 at the genetic level. 
Indeed, we noted a decrease in the mRNA expression of CXCL16 as the metastatic 
potential of cell-lines increased (Fig 2). This was followed with an increase in 
CXCR6 expression as the metastatic potential of the cell-lines increased. It is thus 
possible that the more metastatic tumour cells may respond to CXCL16 by up-
regulating CXCR6 expression first. Taken collectively, it appears that cellular trans-
membrane CXCL16 down-regulation, either at the gene expression level or through 
the shedding process, at primary tumour sites could be a predictive marker for 
metastasis incidence in breast cancer patients and that metastasis of breast tumours are 
at least partly mediated by the regulation of both cellular trans-membrane and cleaved 
soluble CXCL16 at tumour sites, by these two processes. 
 
4.2 RELATIONSHIP BETWEEN TRANS-MEMBRANE CXCL16 
EXPRESSION AND KNOWN BREAST CANCER PATHOLOGICAL 
MARKERS  
Another novel finding that we derived from our immunohistochemistry 
analysis is the relationship between tumour cellular trans-membrane CXCL16 
expression and the expressions of known breast cancer clinicopathological markers 
ER, PR and HER2 (Table 8). Typically, the loss of ER and PR and the gain of HER2 
expressions are linked to poor prognosis and higher incidences of metastasis (62-63). 
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Several recent studies on breast cancer patient samples have also revealed that 
patients diagnosed with the triple negative breast tumour subtype (ER-/PR-/HER2-) 
and the ER-/PR-/HER2+ breast tumour subtype have a higher chance of developing 
more aggressive tumours and thus these patients demonstrate a higher tendency to be 
susceptible to metastasis (and particularly develop brain metastases) (64-66). Our 
results seem to suggest that trans-membrane CXCL16 expression is positively 
associated with ER and PR expression, i.e, loss of CXCL16 expression is consistent 
with the loss of ER and PR expression. Conversely, CXCL16 expression is negatively 
associated with HER2 expression, i.e, the loss of CXCL16 expression is consistent 
with the gain of HER2 expression. This is an interesting observation since the down-
regulation of trans-membrane CXCL16 seems to be associated with the ER 
negative/PR negative/HER2 positive expression pattern, which confers a higher 
metastatic potential to tumours that possess this expression profile. This adds another 
link to our belief that trans-membrane CXCL16 down-regulation could possibly 
increase the incidence of metastasis. Taking the expression patterns and the trends 
observed into account, our data seems to suggest that breast tumour trans-membrane 
CXCL16 expression could be a viable clinicopathological breast cancer marker to 
predict metastasis occurrence.  
 
4.3 EFFECT OF SOLUBLE CXCL16 ON MCF-7 AND MDA-MB-231 BREAST 
CANCER CELLS MIGRATION 
Through this study, we have shown with the highly metastatic MDA-MB-231 
and poorly metastatic MCF-7 breast cancer cell-lines that soluble CXCL16 (which is 
similar to cleaved soluble CXCL16 mentioned throughout) does not increase breast 
cancer cell proliferation but increases cell motility. While lower CXCL16 mRNA 
  71
levels and loss of cellular trans-membrane CXCL16 expression is associated with 
higher incidence of breast cancer metastasis, the presence of increased levels of 
soluble CXCL16 increases cell migration and this could possibly increase the ability 
of CXCR6-expressing breast cancer cells to migrate faster to distant sites to form 
metastases. While increased invasiveness enhances the establishment of metastases at 
distant sites, it is also possible that the ability of cells to respond to chemokine 
signalling, such as CXCL16 signalling, could increase the rate of metastases 
formation since cells may be able to migrate faster to these sites to invade and 
establish metastatic colonies. We have shown in this study that cleaved soluble and 
cellular trans-membrane CXCL16 probably play differential roles in influencing 
metastasis, whereby the availability of excess cleaved soluble form seems to favour 
metastasis while the high expression of trans-membrane form seems to favour anti-
metastastic behaviour.  
Meijer et al (2008) (19), in their work in relation to cancer cell proliferation, 
have proposed the speculation and the new paradigm in CXCL16-signalling that 
soluble and trans-membrane CXCL16 downstream signalling pathways are probably 
dissimilar. We have further added another functional aspect (i.e cell migration and 
metastasis) that can be linked to the different signalling mechanisms mediated by the 
respective CXCL16 forms. With this new paradigm, future work in this field would 
most likely address these differential signalling mechanisms and delineate the effects 
brought about by the different forms of CXCL16, when studying diseases such as 
cancer and rheumatoid arthritis. 
It is also likely that the two variations to CXCL16 signalling mechanisms are 
maintained and regulated by the tumour cells themselves. For example, as mentioned 
above, the loss of trans-membrane CXCL16 in tumour cells may be due to the 
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shedding of CXCL16 by ADAMs and the eventual increase in soluble CXCL16 as a 
result. This would first reduce trans-membrane CXCL16-CXCR6 signalling between 
tumour cells. The resulting increase in soluble CXCL16 could then tilt the signalling 
balance towards the soluble CXCL16-CXCR6 signalling pathway and induce some 
tumour cells to acquire a more aggressive and motile phenotype that could aid their 
migration to other sites. 
We have also noted that soluble CXCL16 treatment has the ability to 
genetically program breast cancer cells to release certain soluble factors that could 
increase cell migratory abilities of cancer cells that were not pre-exposed to CXCL16, 
as seen in our results in Figure 8. Taken in the context of the tumour 
microenvironment, the release of these factors could possibly stimulate the neoplastic 
progression of even normal breast cells and influence a large group of malignant cells 
to acquire a metastatic phenotype when the concentration of these factors is great 
enough to stimulate these cells. Certainly, the release of these factors would be an 
interesting point for analysis and this adds further interest to the role chemokines play 
in genetically ‘priming’ cancer cells to adopt a more aggressive nature. In fact, 
identifying the soluble factors found in the CXCL16-treated cells’ conditioned media 
would allow us to determine novel mechanisms that link the soluble CXCL16 
signalling pathway to these soluble factors. Perhaps a proteomics analysis of the 
conditioned media from the soluble CXCL16 experiments could be carried out to 
identity these soluble factors. Alternatively, an ELISA array could be utilised to 





4.4 REAL-TIME PCR GENE EXPRESSION ANALYSIS OF TREATED 
AND/OR UNTREATED MDA-MB-231 CELLS IN WOUND HEALING 
ASSAYS 
The real-time PCR analysis carried out on the metastasis-related gene array 
yielded few candidate genes to substantiate the observations seen in the wound 
healing experiments. To recap, the primary goal was to find candidate genes whose 
expressions were altered upon scratch-wound infliction, CXCL16 treatment and ERK 
pathway inhibition by U0126, and thereby explain the observations seen in our 
scratch-wound assay experiments. As described in our results section, there were only 
3 genes (SSTR2, MMP13 and NR4A3) that could somewhat substantiate the 
observations seen in the wound-healing experiments.  
The small number of gene expression changes described above is indeed a 
surprising observation. While we believe that the experiments were conducted 
rigourly, it is possible that two factors could have contributed to this observation. 
First, it could be possible that the 24-hr post-scratch time-point may have been ‘too 
late’ to capture other notable changes in gene expression. Secondly, since RNA was 
harvested from all the cells in the well instead of just from cells juxtaposed to, and 
migrating into the wound, significant patterns in gene expressions in the migrating 
cells could have also been masked. Addressing these two possibilities could thus be of 
interest for follow-up experiments. 
In our study, we picked the somatostatin receptor SSTR2 as a candidate gene 
to pursue a simple preliminary analysis to determine if it has a part to play in the cell 
migration observations noted in our wound healing assays. The somatostatin pathway 
is activated by the peptide hormone somatostatin and is regulated by 5 different 
Somatostatin Receptors (SSTR), SSTR1 to SSTR5 (67-68). All 5 receptors are 
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coupled to G-Proteins that mediate several signal transductions through the down-
regulation of Adenylate Cyclase and Tyrosine Phosphatases for example (67-69). 
Buchan et al (2002) (69) have previously shown that somatostatin was able to inhibit 
cell migration in CCL39 fibroblast cells, though this was through the activation of 
SSTR1. This was achieved through the inhibition of Rho protein activity and actin 
fibre formation in these cells. Pyronnet et al (2008) (59) have also reviewed several 
studies that have provided evidence that somatostatin signalling through SSTR2 
mediates anti-tumour effects by inhibiting tumour growth and metastasis. This is 
achieved in several ways where the activated somatostatin signalling pathway can 
induce cancer cell apoptosis, inhibit autocrine/paracrine growth factor production and 
growth factor-mediated mitogenic signalling in cancer cells, reduce cancer cell 
invasion and demote the process of angiogenesis in the tumour microenvironment (59, 
70-74). Because SSTR2 is an important receptor in the somatostatin signalling 
pathway (59, 68), and it is known to promote anti-tumour and anti-metastatic effects, 
we predicted that SSTR2 could be important to the CXCL16-mediated observations 
witnessed in our wound healing assays since SSTR2 expression was reduced in the 
CXCL16-treated wound samples as compared to the untreated wound samples. 
However our preliminary work to determine the functional relevance of SSTR2 in our 
wound healing assays has shown that SSTR2 is not functionally linked to the 
CXCL16-mediated increase in cell migration though the inhibition of SSTR2 per se 
with a potent inhibitor (CYANAMID) could increase the cell migration capabilities of 
MDA-MB-231 cells. Thus, while the somatostatin signalling pathway contributes to 
cell motility, its mode of action is not likely linked to the CXCL16 signalling pathway 
even though the expression of SSTR2 seems to be influenced by CXCL16. Further 
analysis is however required to conclusively understand the role of the somatostain 
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signalling pathway, if active, in our assays and in the context of breast cancer cell 
migration. 
The real-time PCR analysis however has highlighted the importance of the 
ERK signalling pathway in the context of breast cancer cell migration. Various genes 
are under the control of this important signalling pathway and from the PCR analysis 
results (Tables 12-15), it is evident that the downstream genes under the control of the 
ERK pathway should be the point of focus to determine candidates that could control 
cell migration and any acquired increase in cell migration. For example, our results 
reveal that several extra-cellular matrix proteins such as MMP7, MMP9, MMP11 and 
MMP13 and chemokines/chemokine receptors such as IL18 and CXCR4 are directly 
regulated by the ERK pathway and the inhibition of the ERK pathway could change 
the expression of these genes by more than 1.5 fold. These are widely studied genes 
and there is substantial data to suggest that they contribute significantly to 
tumourigenesis and metastasis (36, 75-78). For example, MMP9 is believed to be very 
important to the process of tumour-induced angiogenesis for the establishment of 
tumours (79).  Thus these genes could be analysed further in the wound healing 
assays to determine if they could be viable targets to curb the increased migratory 
potential of the cells. 
We have also noted the increased expression of MMP13 in the CXCL16 and 
U0126-treated samples compared to the CXCL16-treated samples (Fig 11). This may 
come across as a conflict since the increased MMP expression is contradictorily 
accompanied with decreased cell migration instead of increased cell migration. We 
however hypothesise that there may be several reasons why this increase in 
expression is not accompanied with the concomitant increase in cell migration: first, 
the increased MMP13 expression may probably have an effect on cell invasion (which 
  76
can be visualised in a matrigel invasion assay) rather than cell migration in our wound 
healing assays (where the requirement for any MMP-mediated matrix degradation in 
effecting cell migration is perhaps minimal). Second, an increased genetic expression 
of MMP13 may not be representative of an increase in active secreted MMP13. Third, 
the ERK pathway inhibition could have had such a negative impact on the cells’ 
ability to migrate that even an increase in functional MMP13 may not be enough to 
supersede the effect of ERK inhibition on cell migration. These speculations could be 
tested further in future analyses.      
Moreover, as seen in our analysis, the ERK pathway also directly regulates 
several transcription factors such as ETV4. It is thus likely that several genes 
modulated by these transcription factors could also be contributing in some way to the 
metastatic process and specifically to cell motility. Noting the seemingly important 
role of the ERK pathway in regulating the expression of several genes, inhibiting 
ERK activity at the generic level may not necessarily be the best therapy as it is likely 
that the resultant inhibition of these transcription factors and other genes could also 
inevitably inhibit the expression of several tumour and metastasis suppressor genes. 
Thus inhibiting down-stream targets may be more worthwhile. Currently, attention is 
already given to formulating therapies that target some of the aforementioned MMPs 
(80-84) and CXCR4 (85), which in our study appear to be down-stream of ERK. The 
efficacy of these therapies could also be accessed further in the context of curbing 
chemokine-induced increase in cell migration.  
 
4.5 CONCLUSION 
In conclusion, this study has revealed that the cellular trans-membrane and 
cleaved soluble forms of CXCL16 affect tumour cells in different ways and thus play 
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different roles in the context of breast cancer. The initial hypothesis thus holds true; 
that CXCL16 plays a role in mediating breast cancer cell migration and metastasis. 
Specifically, trans-membrane CXCL16 is down-regulated in breast tumours as 
compared to normal breast tissues and this expression appears to inhibit metastasis. 
Data from in-vitro assays suggest that soluble CXCL16 increases breast cancer cell 
migration. Soluble CXCL16 partly achieves this role by genetically re-programming 
cells to induce the expression of soluble factors that could further re-program these 
cells to become more motile. This phenomenon can be controlled by the ERK 
signalling pathway, which seems to regulate many genes that could determine the 
phenotype of breast cancer cells and their migratory abilities. Further analysis is 
required to determine the identity of these genes and their ability to attenuate the 
increase in cell migration witnessed after CXCL16 treatment, without the need to 
inhibit global ERK signalling in cells.             
 
4.6 FUTURE DIRECTION AND STUDIES 
This study has added further evidence to the belief that trans-membrane and 
soluble forms of CXCL16 signal through different pathways in cancer cells. While 
Meijer et al (2008) (19) have demonstrated this difference in the context of cell 
proliferation and has shown that trans-membrane CXCL16 signals through Gi protein 
signalling pathways, the alternate signalling pathway that soluble CXCL16 signals 
through has not been elucidated and clearly understood. Because the effects of both 
CXCL16 forms are reciprocally different in the context of cell proliferation and 
metastasis, more work is required to clearly characterise the pathways that soluble and 
trans-membrane CXCL16 activate and the downstream pathways that they regulate. 
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The question thus remains on how both forms of CXCL16 bring about the 
differing observations noted in our analysis and the precise molecular players in the 
process. This is a key question that will be answered in our future analysis. 
Our real-time PCR results have demonstrated that the ERK pathway is an 
important regulator of cell migration and has revealed several ERK pathway-regulated 
genes that could be crucial to cell migration. Further analysis is thus required to 
validate the PCR array screening results and determine if one or more of these 
candidates could be targeted instead of the entire ERK pathway, to curb CXCL16-
induced cell migration increase.  
The conditioned media experiments have also shown that one or more soluble 
proteins that are induced by CXCL16 mediate the increase in cell migration as a result 
of CXCL16 treatment. A proteomics analysis to determine and differentiate the 
proteins in the conditioned media of CXCL16-treated breast cancer cells and their 
untreated counterparts will thus provide a shortlist of molecular candidates that could 
be linked to the increase in cell migration as a result of CXCL16 treatment. This 
analysis could start with a focused ELISA array analysis of the conditioned media. 
A second question that requires further analysis is the extent to which CXCR6 
expression regulates the signalling mechanisms of both forms of CXCL16 and the 
role it plays in tumourigenesis and metastasis. A comprehensive 
immunohistochemistry analysis of CXCR6 expression in tumour tissue, normal breast 
tissue and tumour infiltrating lymphocytes will provide vital information that will 
help determine if the regulation of CXCR6 expression eventually controls the extent 
to which CXCL16 influences the tumour microenvironment. In our experiments, the 
highly metastatic MDA-MB-231 cells had the highest CXCR6 expression level 
amongst all cell-lines we analysed and were more responsive to soluble CXCL16 than 
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the poorly metastatic MCF-7 cells that had a lower CXCR6 expression level. It is thus 
reasonable to speculate that CXCR6 expression is perhaps a key regulator and is more 
important than CXCL16 expression per se, in determining the aggressiveness of 
tumours and the processes that lead to the eventual onset of metastasis. 
Finally, the clinicopathological relevance of both soluble and trans-membrane 
CXCL16 requires further analysis as our data seems to suggest that CXCL16 could be 
a viable prognostic breast cancer marker. If it is indeed true that the loss of trans-
membrane CXCL16 is due to the proteolytic cleavage by ADAMs to produce soluble 
CXCL16, then it is also possible that this increase in soluble CXCL16 could also be 
detected in the serum of these patients. In this respect, the presence of elevated 
soluble CXCL16 levels in the serum could itself serve as a quick diagnostic and 
prognostic marker. A second point to note is the presence of CXCL16-positive 
lymphocytes in the population of tumour-infiltrating lymphocytes. If there is indeed a 
correlation between the relative abundance of these lymphocytes in the blood 
circulation of breast cancer patients and other clinicopathological parameters such as 
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SUPPLEMENTARY RESULTS ATTACHMENT 1    
        
 Data set 1: Gene expression changes after wound infliction in untreated MDA-MB-231 cell setups  
        
 Genes up-regulated  Genes down-regulated 







 A04 CD44 1.0867  A01 APC -1.0792 
 A05 CDH1 1.014  A02 BRMS1 -1.014 
 A10 COL4A2 1.0317  A03 CCL7 -1.0246 
 A11 CST7 1.0175  A06 CDH11 -1.021 
 B01 CTNNA1 1.021  A07 CDH6 -1.0246 
 B02 CTSK 1.0905  A08 CDKN2A -1.0246 
 B05 CXCR4 1.0905  A09 CHD4 -1.0035 
 B06 DENR 1.0389  A12 CTBP1 -1.0317 
 B07 EPHB2 1.1408  B03 CTSL1 -1.0246 
 B09 EWSR1 1.0175  B04 CXCL12 -1.0246 
 B11 FGFR4 1.014  B08 ETV4 -1.0105 
 B12 FLT4 1.0105  B10 FAT -1.0461 
 C02 FXYD5 1.0281  C01 FN1 -1.0461 
 C03 GNRH1 1.0905  C04 KISS1R -1.0246 
 C06 HPSE 1.1329  C05 HGF -1.0246 
 C07 HRAS 1.057  C09 IGF1 -1.0246 
 C08 HTATIP2 1.0353  C12 IL8RB -1.0246 
 C10 IL18 1.0792  D05 KRAS -1.0317 
 C11 IL1B 1.0353  D07 MCAM -1.007 
 D01 ITGA7 1.181  D08 MDM2 -1.0035 
 D02 ITGB3 1  D12 MMP10 -1.0246 
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 D03 CD82 1.0281  E01 MMP11 -1.007 
 D04 KISS1 1.1769  E03 MMP2 -1.0246 
 D06 RPSA 1.0175  E04 MMP3 -1.0246 
 D09 MET 1.1057  E05 MMP7 -1.3059 
 D10 METAP2 1.1607  E08 MTSS1 -1.2527 
 D11 MGAT5 1.0317  F04 PLAUR -1.007 
 E02 MMP13 2.035  F06 PTEN -1.0353 
 E06 MMP9 1.2834  F08 RORB -1.0246 
 E07 MTA1 1.0425  G02 SYK -1.0246 
 E09 MYC 1.0792  G06 TIMP3 -1.0246 
 E10 MYCL1 1.2142  G07 TIMP4 -1.1251 
 E11 NF2 1.057  G08 TNFSF10 -1.1057 
 E12 NME1 1.0105  G09 TP53 -1.0035 
 F01 NME2 1.0461  G10 TRPM1 -1.0246 
 F02 NME4 1.1728  G11 TSHR -1.0246 
 F03 NR4A3 1.2354  G12 VEGFA -1.0175 
 F05 PNN 1.0105  H03 RPL13A -1.0035 
 F07 RB1 1.0175  H05 ACTB -1 
 F09 SET 1     
 F10 SMAD2 1.0497     
 F11 SMAD4 1.021     
 F12 SRC 1.0607     
 G01 SSTR2 1.9386     
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 G03 TCF20 1.1851     
 G04 TGFB1 1.0105     
 G05 TIMP2 1.0534     
 H01 B2M 1.0035     
 H02 HPRT1 1.0105     
 H04 GAPDH 1.0246     
 H05 ACTB 1     
        
 Data set 2: Gene expression changes in CXCL16-treated wound setups vs untreated wound setups  
        
 Genes up-regulated  Genes down-regulated 







 A01 APC 1.0305  A02 BRMS1 -1.0116 
 A03 CCL7 1.1878  A04 CD44 -1.0257 
 A06 CDH11 1.0521  A05 CDH1 -1.0401 
 A07 CDH6 1.1878  A09 CHD4 -1.0401 
 A08 CDKN2A 1.1878  A10 COL4A2 -1.0116 
 A11 CST7 1.1434  A12 CTBP1 -1.0509 
 B03 CTSL1 1.1878  B01 CTNNA1 -1.0116 
 B04 CXCL12 1.1878  B02 CTSK -1.1303 
 B10 FAT 1.0892  B05 CXCR4 -1.0116 
 C04 KISS1R 1.1878  B06 DENR -1.0187 
 C05 HGF 1.1878  B07 EPHB2 -1.0437 
 C07 HRAS 1.1083  B08 ETV4 -1.0365 
 C09 IGF1 1.1878  B09 EWSR1 -1.203 
 C12 IL8RB 1.1878  B11 FGFR4 -1.2585 
 D06 RPSA 1.0743  B12 FLT4 -1.1109 
 D12 MMP10 1.1878  C01 FN1 -1.0401 
 E01 MMP11 1.0234  C02 FXYD5 -1.0293 
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 E03 MMP2 1.1878  C03 GNRH1 -1.4109 
 E04 MMP3 1.1878  C06 HPSE -1.1225 
 E05 MMP7 1.1878  C08 HTATIP2 -1.0257 
 E06 MMP9 1.2556  C10 IL18 -1.1303 
 E12 NME1 1.0558  C11 IL1B -1.0257 
 F01 NME2 1.078  D01 ITGA7 -1.15 
 F02 NME4 1.0558  D02 ITGB3 -1.2114 
 F06 PTEN 1.0023  D03 CD82 -1.0187 
 F08 RORB 1.1878  D04 KISS1 -1.0842 
 F09 SET 1.0128  D05 KRAS -1.0842 
 G02 SYK 1.1878  D07 MCAM -1.0437 
 G06 TIMP3 1.1878  D08 MDM2 -1.0582 
 G07 TIMP4 1.2426  D09 MET -1.0437 
 G09 TP53 1.0449  D10 METAP2 -1.0012 
 G10 TRPM1 1.1878  D11 MGAT5 -1.073 
 G11 TSHR 1.1878  E02 MMP13 -1.0805 
 H01 B2M 1.0023  E07 MTA1 -1.1032 
 H03 RPL13A 1.0341  E08 MTSS1 -1.0805 
 H04 GAPDH 1.1837  E09 MYC -1.2983 
     E10 MYCL1 -1.088 
     E11 NF2 -1.1264 
     F03 NR4A3 -1.7921 
     F04 PLAUR -1.0116 
     F05 PNN -1.107 
     F07 RB1 -1.0329 
     F10 SMAD2 -1.158 
     F11 SMAD4 -1.0293 
     F12 SRC -1.2541 
     G01 SSTR2 -1.9009 
     G03 TCF20 -1.3165 
     G04 TGFB1 -1.0767 
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     G05 TIMP2 -1.0293 
     G08 TNFSF10 -1.0187 
     G12 VEGFA -1.0473 
     H02 HPRT1 -1.0222 
     H05 ACTB -1.0365 
        
 
 Data set 3: Gene expression changes in CXCL16-treated wound setups vs untreated and unwounded setups  
        
 Genes up-regulated  Genes down-regulated 







 A03 CCL7 1.1594  A01 APC -1.0473 
 A04 CD44 1.0595  A02 BRMS1 -1.0257 
 A06 CDH11 1.0305  A05 CDH1 -1.0257 
 A07 CDH6 1.1594  A09 CHD4 -1.0437 
 A08 CDKN2A 1.1594  A12 CTBP1 -1.0842 
 A10 COL4A2 1.0198  B02 CTSK -1.0365 
 A11 CST7 1.1634  B08 ETV4 -1.0473 
 B01 CTNNA1 1.0093  B09 EWSR1 -1.1824 
 B03 CTSL1 1.1594  B11 FGFR4 -1.2411 
 B04 CXCL12 1.1594  B12 FLT4 -1.0994 
 B05 CXCR4 1.078  C01 FN1 -1.088 
 B06 DENR 1.0198  C02 FXYD5 -1.0012 
 B07 EPHB2 1.093  C03 GNRH1 -1.2938 
 B10 FAT 1.0413  C10 IL18 -1.0473 
 C04 KISS1R 1.1594  D02 ITGB3 -1.2114 
 C05 HGF 1.1594  D05 KRAS -1.1186 
 C06 HPSE 1.0093  D07 MCAM -1.0509 
 C07 HRAS 1.1715  D08 MDM2 -1.0619 
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 C08 HTATIP2 1.0093  D11 MGAT5 -1.0401 
 C09 IGF1 1.1594  E05 MMP7 -1.0994 
 C11 IL1B 1.0093  E07 MTA1 -1.0582 
 C12 IL8RB 1.1594  E08 MTSS1 -1.3535 
 D01 ITGA7 1.0269  E09 MYC -1.203 
 D03 CD82 1.0093  E11 NF2 -1.0656 
 D04 KISS1 1.0855  F03 NR4A3 -1.4506 
 D06 RPSA 1.093  F04 PLAUR -1.0187 
 D09 MET 1.0595  F05 PNN -1.0956 
 D10 METAP2 1.1594  F06 PTEN -1.0329 
 D12 MMP10 1.1594  F07 RB1 -1.0151 
 E01 MMP11 1.0163  F10 SMAD2 -1.1032 
 E02 MMP13 1.8834  F11 SMAD4 -1.0081 
 E03 MMP2 1.1594  F12 SRC -1.1824 
 E04 MMP3 1.1594  G03 TCF20 -1.1109 
 E06 MMP9 1.6114  G04 TGFB1 -1.0656 
 E10 MYCL1 1.116  G08 TNFSF10 -1.1264 
 E12 NME1 1.0668  G12 VEGFA -1.0656 
 F01 NME2 1.1277  H02 HPRT1 -1.0116 
 F02 NME4 1.2383  H05 ACTB -1.0365 
 F08 RORB 1.1594     
 F09 SET 1.0128     
 G01 SSTR2 1.0198     
 G02 SYK 1.1594     
 G05 TIMP2 1.0234     
 G06 TIMP3 1.1594     
 G07 TIMP4 1.1045     
 G09 TP53 1.0413     
 G10 TRPM1 1.1594     
 G11 TSHR 1.1594     
 H01 B2M 1.0058     
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 H03 RPL13A 1.0305     
 H04 GAPDH 1.2128     
        
 
 
Data set 4: Gene expression changes in CXCL16 and U0126-treated wound setups vs CXCL16-treated 
wound setups  
        
 Genes up-regulated  Genes down-regulated 







 A01 APC 1.0521  A02 BRMS1 -1.0805 
 B02 CTSK 1.3645  A03 CCL7 -1.2894 
 B11 FGFR4 1.7271  A04 CD44 -1.3488 
 B12 FLT4 1.4777  A05 CDH1 -1.0329 
 C08 HTATIP2 1.4028  A06 CDH11 -1.7371 
 C11 IL1B 1.1514  A07 CDH6 -1.2894 
 D01 ITGA7 1.4323  A08 CDKN2A -1.2894 
 D07 MCAM 1.0198  A09 CHD4 -1.0046 
 E01 MMP11 1.7818  A10 COL4A2 -1.6548 
 E02 MMP13 1.8769  A11 CST7 -2.3322 
 E05 MMP7 5.9312  A12 CTBP1 -1.0693 
 E09 MYC 1.1434  B01 CTNNA1 -1.1865 
 E10 MYCL1 1.2731  B03 CTSL1 -1.2894 
 F03 NR4A3 2.3839  B04 CXCL12 -1.2894 
 F10 SMAD2 1.1083  B05 CXCR4 -5.6634 
 F12 SRC 1.3134  B06 DENR -1.2672 
 G01 SSTR2 1.7331  B07 EPHB2 -1.0767 
 H01 B2M 1.0705  B08 ETV4 -22.4971 
     B09 EWSR1 -1.1947 
     B10 FAT -1.5122 
     C01 FN1 -1.3915 
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     C02 FXYD5 -1.3302 
     C03 GNRH1 -1.5494 
     C04 KISS1R -1.2894 
     C05 HGF -1.2894 
     C06 HPSE -1.0918 
     C07 HRAS -1.7736 
     C09 IGF1 -1.2894 
     C10 IL18 -1.6663 
     C12 IL8RB -1.2894 
     D02 ITGB3 -1.3724 
     D03 CD82 -4.2772 
     D04 KISS1 -2.3001 
     D05 KRAS -1.2198 
     D06 RPSA -1.321 
     D08 MDM2 -1.3964 
     D09 MET -2.0729 
     D10 METAP2 -1.507 
     D11 MGAT5 -1.4658 
     D12 MMP10 -1.2894 
     E03 MMP2 -1.2894 
     E04 MMP3 -1.2894 
     E06 MMP9 -1.4811 
     E07 MTA1 -1.0473 
     E08 MTSS1 -2.0873 
     E11 NF2 -1.0116 
     E12 NME1 -1.9885 
     F01 NME2 -1.3488 
     F02 NME4 -1.8877 
     F04 PLAUR -1.507 
     F05 PNN -1.2672 
     F06 PTEN -1.0116 
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     F07 RB1 -1.632 
     F08 RORB -1.2894 
     F09 SET -1.4356 
     F11 SMAD4 -1.1147 
     G02 SYK -1.2894 
     G03 TCF20 -1.2805 
     G04 TGFB1 -1.0046 
     G05 TIMP2 -1.203 
     G06 TIMP3 -1.2894 
     G07 TIMP4 -2.0873 
     G08 TNFSF10 -1.3819 
     G09 TP53 -1.2411 
     G10 TRPM1 -1.2894 
     G11 TSHR -1.2894 
     G12 VEGFA -1.2326 
     H02 HPRT1 -1.9543 
     H03 RPL13A -1.0293 
     H04 GAPDH -1.7191 
     H05 ACTB -1.0401 
        
 
 
Data set 5: Gene expression changes in CXCL16 and U0126-treated wound setups vs untreated and 
unwounded setups  
        
 Genes up-regulated  Genes down-regulated 







 A01 APC 1.0046  A02 BRMS1 -1.1083 
 B02 CTSK 1.3165  A03 CCL7 -1.1121 
 B07 EPHB2 1.0151  A04 CD44 -1.2731 
 B11 FGFR4 1.3915  A05 CDH1 -1.0595 
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 B12 FLT4 1.3441  A06 CDH11 -1.6857 
 C08 HTATIP2 1.4158  A07 CDH6 -1.1121 
 C11 IL1B 1.162  A08 CDKN2A -1.1121 
 D01 ITGA7 1.4709  A09 CHD4 -1.0485 
 E01 MMP11 1.8108  A10 COL4A2 -1.6226 
 E02 MMP13 3.5349  A11 CST7 -2.0046 
 E05 MMP7 5.3952  A12 CTBP1 -1.1594 
 E06 MMP9 1.088  B01 CTNNA1 -1.1755 
 E10 MYCL1 1.4208  B03 CTSL1 -1.1121 
 F03 NR4A3 1.6434  B04 CXCL12 -1.1121 
 F10 SMAD2 1.0046  B05 CXCR4 -5.2537 
 F12 SRC 1.1109  B06 DENR -1.2426 
 G01 SSTR2 1.7674  B08 ETV4 -23.5611 
 H01 B2M 1.0767  B09 EWSR1 -1.4126 
 H03 RPL13A 1.0012  B10 FAT -1.4523 
     C01 FN1 -1.514 
     C02 FXYD5 -1.3318 
     C03 GNRH1 -2.0046 
     C04 KISS1R -1.1121 
     C05 HGF -1.1121 
     C06 HPSE -1.0817 
     C07 HRAS -1.514 
     C09 IGF1 -1.1121 
     C10 IL18 -1.7451 
     C12 IL8RB -1.1121 
     D02 ITGB3 -1.6625 
     D03 CD82 -4.2379 
     D04 KISS1 -2.1189 
     D05 KRAS -1.3645 
     D06 RPSA -1.2086 
     D07 MCAM -1.0305 
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     D08 MDM2 -1.4828 
     D09 MET -1.9566 
     D10 METAP2 -1.2998 
     D11 MGAT5 -1.5245 
     D12 MMP10 -1.1121 
     E03 MMP2 -1.1121 
     E04 MMP3 -1.1121 
     E07 MTA1 -1.1083 
     E08 MTSS1 -2.8252 
     E09 MYC -1.0521 
     E11 NF2 -1.078 
     E12 NME1 -1.8639 
     F01 NME2 -1.1961 
     F02 NME4 -1.5245 
     F04 PLAUR -1.5351 
     F05 PNN -1.3883 
     F06 PTEN -1.0449 
     F07 RB1 -1.6567 
     F08 RORB -1.1121 
     F09 SET -1.4175 
     F11 SMAD4 -1.1238 
     G02 SYK -1.1121 
     G03 TCF20 -1.4224 
     G04 TGFB1 -1.0705 
     G05 TIMP2 -1.1755 
     G06 TIMP3 -1.1121 
     G07 TIMP4 -1.8899 
     G08 TNFSF10 -1.5565 
     G09 TP53 -1.192 
     G10 TRPM1 -1.1121 
     G11 TSHR -1.1121 
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     G12 VEGFA -1.3134 
     H02 HPRT1 -1.977 
     H04 GAPDH -1.4175 











 HUMAN TUMOUR METASTASIS GENE PCR ARRAY DETAILS (PAHS-028A) 
 
Position 01 02 03 04 05 06 07 08 09 10 11 12 
A APC BRMS1 CCL7 CD44 CDH1 CDH11 CDH6 CDKN2A CHD4 COL4A2 CST7 CTBP1 
B CTNNA1 CTSK CTSL1 CXCL12 CXCR4 DENR EPHB2 ETV4 EWSR1 FAT1 FGFR4 FLT4 
C FN1 FXYD5 GNRH1 KISS1R HGF HPSE HRAS HTATIP2 IGF1 IL18 IL1B IL8RB 
D ITGA7 ITGB3 CD82 KISS1 KRAS RPSA MCAM MDM2 MET METAP2 MGAT5 MMP10 
E MMP11 MMP13 MMP2 MMP3 MMP7 MMP9 MTA1 MTSS1 MYC MYCL1 NF2 NME1 
F NME2 NME4 NR4A3 PLAUR PNN PTEN RB1 RORB SET SMAD2 SMAD4 SRC 
G SSTR2 SYK TCF20 TGFB1 TIMP2 TIMP3 TIMP4 TNFSF10 TP53 TRPM1 TSHR VEGFA 
H B2M HPRT1 RPL13A GAPDH ACTB HGDC RTC RTC RTC PPC PPC PPC 
 
Position Symbol Description  Position Symbol Description 
A01 APC Adenomatous polyposis coli 
 
E01 MMP11 
Matrix metallopeptidase 11 
(stromelysin 3) 
  106
A02 BRMS1 Breast cancer metastasis suppressor 1 
 
E02 MMP13 
Matrix metallopeptidase 13 
(collagenase 3) 
A03 CCL7 Chemokine (C-C motif) ligand 7 
 
E03 MMP2 
Matrix metallopeptidase 2 (gelatinase 
A, 72kDa gelatinase, 72kDa type IV 
collagenase) 
A04 CD44 CD44 molecule (Indian blood group) 
 
E04 MMP3 
Matrix metallopeptidase 3 
(stromelysin 1, progelatinase) 
A05 CDH1 




Matrix metallopeptidase 7 (matrilysin, 
uterine) 
A06 CDH11 




Matrix metallopeptidase 9 (gelatinase 
B, 92kDa gelatinase, 92kDa type IV 
collagenase) 
A07 CDH6 
Cadherin 6, type 2, K-cadherin (fetal 
kidney) 
 
E07 MTA1 Metastasis associated 1 
A08 CDKN2A 
Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
 
E08 MTSS1 Metastasis suppressor 1 
A09 CHD4 




V-myc myelocytomatosis viral 
oncogene homolog (avian) 
A10 COL4A2 Collagen, type IV, alpha 2 
 
E10 MYCL1 
V-myc myelocytomatosis viral 
oncogene homolog 1, lung carcinoma 
derived (avian) 
A11 CST7 Cystatin F (leukocystatin) 
 
E11 NF2 Neurofibromin 2 (merlin) 
  107
A12 CTBP1 C-terminal binding protein 1 
 
E12 NME1 
Non-metastatic cells 1, protein 
(NM23A) expressed in 
B01 CTNNA1 
Catenin (cadherin-associated protein), 
alpha 1, 102kDa 
 
F01 NME2 
Non-metastatic cells 2, protein 
(NM23B) expressed in 
B02 CTSK Cathepsin K 
 
F02 NME4 
Non-metastatic cells 4, protein 
expressed in 
B03 CTSL1 Cathepsin L1 
 
F03 NR4A3 
Nuclear receptor subfamily 4, group 
A, member 3 
B04 CXCL12 
Chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1) 
 
F04 PLAUR 
Plasminogen activator, urokinase 
receptor 
B05 CXCR4 Chemokine (C-X-C motif) receptor 4 
 
F05 PNN Pinin, desmosome associated protein 
B06 DENR Density-regulated protein 
 
F06 PTEN Phosphatase and tensin homolog 
B07 EPHB2 EPH receptor B2 
 
F07 RB1 Retinoblastoma 1 
B08 ETV4 Ets variant 4 
 
F08 RORB RAR-related orphan receptor B 
B09 EWSR1 Ewing sarcoma breakpoint region 1 
 
F09 SET SET nuclear oncogene 
  108
B10 FAT1 
FAT tumor suppressor homolog 1 
(Drosophila) 
 
F10 SMAD2 SMAD family member 2 
B11 FGFR4 Fibroblast growth factor receptor 4 
 
F11 SMAD4 SMAD family member 4 
B12 FLT4 Fms-related tyrosine kinase 4 
 
F12 SRC 
V-src sarcoma (Schmidt-Ruppin A-2) 
viral oncogene homolog (avian) 
C01 FN1 Fibronectin 1 
 
G01 SSTR2 Somatostatin receptor 2 
C02 FXYD5 
FXYD domain containing ion transport 
regulator 5 
 
G02 SYK Spleen tyrosine kinase 
C03 GNRH1 
Gonadotropin-releasing hormone 1 
(luteinizing-releasing hormone) 
 
G03 TCF20 Transcription factor 20 (AR1) 
C04 KISS1R KISS1 receptor 
 
G04 TGFB1 Transforming growth factor, beta 1 
C05 HGF 
Hepatocyte growth factor (hepapoietin 
A; scatter factor) 
 
G05 TIMP2 TIMP metallopeptidase inhibitor 2 
C06 HPSE Heparanase 
 
G06 TIMP3 TIMP metallopeptidase inhibitor 3 
C07 HRAS 
V-Ha-ras Harvey rat sarcoma viral 
oncogene homolog 
 
G07 TIMP4 TIMP metallopeptidase inhibitor 4 
  109
C08 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 
 
G08 TNFSF10 
Tumor necrosis factor (ligand) 
superfamily, member 10 
C09 IGF1 
Insulin-like growth factor 1 
(somatomedin C) 
 






Transient receptor potential cation 
channel, subfamily M, member 1 
C11 IL1B Interleukin 1, beta 
 
G11 TSHR Thyroid stimulating hormone receptor 
C12 IL8RB Interleukin 8 receptor, beta 
 
G12 VEGFA Vascular endothelial growth factor A 
D01 ITGA7 Integrin, alpha 7 
 
H01 B2M Beta-2-microglobulin 
D02 ITGB3 
Integrin, beta 3 (platelet glycoprotein 





D03 CD82 CD82 molecule 
 
H03 RPL13A Ribosomal protein L13a 






V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
 
H05 ACTB Actin, beta 
  110
D06 RPSA Ribosomal protein SA 
 
H06 HGDC Human Genomic DNA Contamination 
D07 MCAM Melanoma cell adhesion molecule 
 
H07 RTC Reverse Transcription Control 
D08 MDM2 
Mdm2 p53 binding protein homolog 
(mouse) 
 
H08 RTC Reverse Transcription Control 
D09 MET 
Met proto-oncogene (hepatocyte 
growth factor receptor) 
 
H09 RTC Reverse Transcription Control 
D10 METAP2 Methionyl aminopeptidase 2 
 





H11 PPC Positive PCR Control 
D12 MMP10 
Matrix metallopeptidase 10 
(stromelysin 2) 
 
H12 PPC Positive PCR Control 
 
